










































































Oligodendrocytes  are  the  principal  target  of  immune  attack  in  multiple  sclerosis 
(MS),  where  the  immune  system  attacks  the  myelin  sheath,  leading  to 
oligodendrocyte demise, compromised axonal saltatory conduction and eventually 
neuronal  degeneration.  Microglia  are  also  implicated  in  MS  pathology  and  are 
present in lesions in an activated state. To study the effects of activated microglia on 
oligodendrocyte precursor cells (OPCs) or mature oligodendrocytes, primary cultures 
of  microglia,  oligodendrocytes,  or  co‐cultures  of  the  two  cell  populations  were 
developed. Microglia activated with lipopolysaccharide (LPS), were toxic to OPCs and 
mature  oligodendrocytes  in  co‐culture.  This  toxicity  was  mediated  by  tumour 
necrosis  factor  α  (TNF‐α)  released  from  microglia.  Microglial  activation  with  the 
blood‐borne  proteins  (BBPs)  fraction  V  albumin,  fibrinogen  and  fibrin  was  also 
investigated.  BBPs  enter  the  brain  after  blood‐brain  barrier  disruption,  a  typical 
event in MS, so their differential effect upon microglial activation and subsequently 
oligodendrocyte  lineage  cell  maturation  survival  was  studied.  BBPs  had  distinct 
effects on microglial activation and oligodendrocyte cell toxicity. Fraction V albumin 
and  fibrin  were  directly  toxic  to  oligodendrocytes  while  microglial  activation 
protected oligodendrocytes in co‐culture. Fibrin also inhibited OPC maturation into 
myelinating oligodendrocytes. Fibrinogen activated microglia were toxic to OPCs and 
mature  oligodendrocytes  in  co‐culture.  Attenuation  of  microglial  induced 
oligodendrocyte death was attempted by blocking pathways of microglial activation 
such  as  the  Rho‐ROCK  pathway  and  by  modulating  microglial  activation  by 
metabotropic glutamate receptor manipulation. Additionally, ROCK inhibition was 
able to attenuate LPS or BBP activated microglial expression of inducible nitric oxide 
synthase  (iNOS).  Modulation  of  microglial  activation  could  prevent  microglial 
induced  oligodendrocyte  toxicity  and  could  lead  to  strategies  to  slow  disease 
progression in MS patients by protecting mature oligodendrocytes from microglial 
induced death, or most importantly by enhancing survival and maturation of OPCs in 

































































































































































































































































































































































































































































































































































































































































































































































types  in  the  brain  are  microglia,  astrocytes,  oligodendrocytes  and  NG2  glia 
(Nishiyama  et  al.,  2002).  Anatomically  the  mammalian  nervous  system  can  be 













immunologic,  and  scavenging  functions  for  the  CNS  (reviewed  by  Kapoor  et  al., 





CNS,  alas,  it  is  not  invulnerable  to  trauma  and  disease.  The  CNS  is  prone  to 
neurogenetic and metabolic diseases, developmental disorders, neuroinflammatory 
and neurodegenerative diseases of adult life, cerebrovascular diseases, convulsive 











or  inhibitory  manner  by  releasing  excitatory  and  inhibitory  neurotransmitters 



















2+‐  ATPase  and  Na
+/  Ca

























to  control  movement,  accompanied  by  a  well‐described  pathophysiology  of  α‐
synuclein neuronal inclusions in specific regions. Still the aetiology of the disease 


























myelin.  Myelin  is  a  highly  lipidic  compact  membrane  with  a  low  proportion  of 
protein  (15‐30%)  that  wraps  spirally  around  axons  to  form  segments  of  myelin 








1%  of  total  myelin  proteins,  such  as  myelin  oligodendrocyte  protein  (MOG)  and 




regulator  of  endothelial  nitric  oxide  synthase  (Arvanitis  et  al.,  2004). 



























al.,  2001).  During  myelination,  oligodendrocyte  derived  factors  seem  to  be 
responsible  for  the  expression  of  Na(v)1.6  channels  that  cluster  at  the  nodes  of 
Ranvier substituting for the Na(v)1.2 channels that remain scattered on the axons 
(Boiko et al., 2001). This procedure shows how myelinating oligodendrocytes direct 
myelination  and  formation  of  the  myelin  sheath.  One  oligodendrocyte  extends 
multiple processes and is able to myelinate up to 50 axons. At the same time many 
oligodendrocytes  are  required  to  myelinate  one  axon,  each  providing  a  myelin 
sheath section between two nodes of Ranvier (Figure 1.1.3.2).  
   The nervous system can be subjected to demyelinating disorders. Demyelination is 
the  pathological  process  by  which  the  myelin  sheath  is  directly  insulted  and 
disturbed or destroyed, exposing the nerve axons and interrupting transmission. This 
leads to axonal degeneration and neuronal death (reviewed by Franklin & ffrench‐
Constant,  2008).  The  most  common  demyelinating  disorder  is  multiple  sclerosis 
(MS), which will be discussed in Chapters 2 and 3. Genetic abnormalities that affect 
oligodendrocyte  lineage  cells,  collectively  named  leukodystrophies  also  result  in 
demyelination (reviewed by Schiffmann & van der Knaap, 2004). A diagrammatic 












Schematic  representation  of  neurones  with  extended  aligned  nerve  axons 
myelinated by oligodendrocytes. One oligodendrocyte can myelinate many axons as 
















1999;  Kessaris  et  al.,  2004).  OPCs  are  small,  bipolar,  motile  cells  that  can  be 









made  multiple  contacts  with  nerve  axons  (Back  et  al.,  2002).  Cell  maturation  is 




of  myelination  are  thyroid  hormone  thyroxine  (Baas  et  al.,  2002),  erythropoietin 
(Sugawa et al., 2002) and neurotrophin‐3 (NT‐3; Rubio et al., 2004). Intracellularly, 
activation of Src family Fyn tyrosine kinase (Osterhout et al., 1999), protein kinase C 
(PKC)  and  mitogen‐activated  protein  kinase  signalling  are  required  for  successful 
myelination (reviewed by Stariha & Kim, 2001). 
   In  the  adult  CNS,  a  population  of  cells  resembling  OPCs,  with  a  slow  rate  of 
migration and a long cell cycle, remains and proliferates actively (Wolswijk & Noble, 
1989). These cells make up around 3‐9% of the glial cell population in the adult CNS 
and  are  known  as  NG2  glia,  since  they  stain  with  the  OPC  specific  marker  NG2 
(Dawson et al., 2003). Their function is still under intense research. In the healthy   27 
brain they seem to have a regulatory role. In the rat spinal cord NG2 glia were shown 




vitro,  NG2  cells  act  as  O‐2A  progenitors  and  differentiate  into  A2B5  and  GFAP 
(astrocyte marker) positive cells and less often into oligodendrocytes (Scolding et al., 
1995). It should be noted here that in vitro, in the presence of serum, OPCs, often 















and  differentiate  into  mature  oligodendrocytes  (reviewed  by  Franklin  &  ffrench‐
Constant, 2008). The two different steps required for remyelination are migration 
and  proliferation  of  the  precursors,  followed  by  their  switch  from  a  migratory‐
proliferating phenotype to a differentiating one. The factors that regulate these two 
phenotypes are distinct and inhibitory to each other. PDGF‐AA and FGF‐2 are crucial 




occasions.  As  demonstrated  by  the  presence  of  quiescent  OPCs  in  chronically 
demyelinated areas of the brain (Wolswijk, 1998), remyelination failure is more likely 
due to failure in OPC differentiation rather than failure in OPC recruitment. There is 








Schematic  representation  of  the  major  steps  in  oligodendrocyte  precursor  cell 
maturation. Some of the markers that identify the developmental status of the cell 
are  listed.  Oligodendrocyte  precursor  cells  proliferate  and  migrate  under  the 
guidance  of  platelet‐derived  growth  factor  AA  (PDGF‐AA)  and  fibroblast  growth 
factor 2 (FGF‐2). Pre‐myelinating oligodendrocytes stop proliferating and enter the 
myelination  process,  which  is  facilitated  by  thyroxine  and  the  growth  factors 
neurotrophin‐3 (NT‐3) and erythropoietin, resulting in mature oligodendrocytes with 
myelin  packed  processes.  Abbreviations:  PDGFRα,  platelet‐derived  growth  factor 







   Schwann  cells  are  the  myelinating  cells  of  the  PNS.  In  contrast  to  their  CNS 
counterparts, the oligodendrocytes, they maintain their ability to de‐differentiate, 
re‐enter  mitosis,  proliferate  and  give  rise  to  new  myelinating  cells  following 
demyelination  and  injury.  Unlike  oligodendrocytes,  each  Schwann  cell  only 
myelinates one axon by folding around it. Schwann cells in the mature PNS can be 




   Schwann  cells  are  targeted  in  inherited  disorders  of  the  PNS  such  as  Charcot‐
Marie‐Tooth  (especially  type  1)  and  the  Guillain‐Barré  Syndrome,  leading  to 






































GABA  and  modulate  transmission  (Araque  et  al.,  1998;    Kang  et  al.,  1998).  For   31 
example, elevation of intracellular astrocyte Ca
2+ was shown to potentiate inhibitory 
transmission  in  their  surrounding  neurones  (Kang  et  al.,  1998).  Astrocytes  also 
regulate the function and integrity of the BBB by surrounding the CNS capillaries 
with  endfeet  (see  1.4.1).  Another  important  characteristic  of  astrocytes  is  the 
release of trophic factors such as brain‐derived neurotrophic factor (BDNF) and NT‐3 
that support neuronal and other glial survival (Dreyfus et al., 1999). Astrocytes are 







   When  studying  the  involvement  of  astrocytes  in  the  immune  response  the 












   In  response  to  injury  astrocytes  are  activated,  upregulate  the  expression  of 
intermediate  filaments  such  as  GFAP,  proliferate  and  form  a  dense  network  of 
hypertrophic cells, filling the gaps that result from neuronal or glial degeneration. 
This  procedure  is  called  reactive  gliosis  and  forms  the  glial  scar  (Reier  &  Houle, 
1988). The glial scar is formed following brain injury or neurodegeneration and is 
important for controlling damage at the site of injury and suppressing expansion of   32 
the  damage  to  neighbouring  cells.  Adverse  effects  are  associated  with  glial  scar 
formation,  since  the  glial  scar  is  inhibitory  for  neuronal  and  precursor  cell 
regeneration,  with  important  implications  for  trauma  and  neurodegenerative 
disease (reviewed by Nair et al., 2008). 
   Astrocytes  have  multiple  supportive  functions  in  the  CNS  and  a  neurological 
disorder affecting primarily astrocytes would probably be fatal. Nonetheless they 
can  be  actively  implicated  in  neurodegenerative  disease.  For  example,  it  was 
recently  discovered  that  astrocytes  expressing  mutant  SOD1  could  selectively  kill 
wild type motor neurones inducing an ALS phenotype (Nagai et al., 2007). Astrocytes 








present  in  the  brain  in  a  ramified  state  with  highly  branched  processes.  During 
development and later at postnatal stages, microglia with an amoeboid phenotype 
derived from the myelomonocytic lineage are produced in the bone marrow, invade 
the  CNS  tissue  and  actively  migrate  within  the  brain  parenchyma  to  colonise  all 
regions of the brain (reviewed by Davoust et al., 2008). Amoeboid microglia are also 
believed to play a role in tissue histogenesis through phagocytosis of inappropriate 
and  superfluous  neurones  (Marín‐Teva  et  al.,  2004)  and  through  promotion  of 
axonal  migration  and  growth  (Rakic  &  Zecevic,  2000).  After  colonising  the  CNS, 
amoeboid  cells  acquire  a  ramified  phenotype  and  extend  long  processes. 






microglia  rather  than  ‘resting’  more  successfully  describes  their  function  in  the 











   In  response  to  injury,  infection,  inflammation  or  neurodegeneration  microglia 
rapidly gain macrophage morphology, transform into activated cells and migrate to 
the site of injury (Stence et al., 2001) where they proliferate (Vela et al., 2002). In 
vitro  studies  of  microglial  activation,  proliferation  and  subsequent  apoptosis  are 
informative of the nature of microglial responses and molecular pathways mobilised 
(Kloss et al., 1997; Kingham et al., 1999; Hooper et al., 2005). Following activation 


















in  neurodegenerative  disease  and  modulation  of  the  immune  response  in 
neuroinflammation  (reviewed  by  Lehnardt,  2009).  Interestingly,  microglia  also 
express  a  variety  of  neurotransmitter  receptors,  indicative  of  interplay  between 
microglia  and  neurones  based  on  the  diffusion  properties  of  neurotransmitters 
released from neurones in a paracrine manner. Microglia possess active α‐amino‐3‐
hydroxyl‐5‐methyl‐4‐isoxazolepropionic acid  (AMPA) and metabotropic glutamate 
receptors,  γ‐aminobutyric  acid  B  (GABAB),  purinergic,  adenosinergic,  cholinergic, 
cannabinoid,  adrenergic  and  dopaminergic  receptors,  as  well  as  receptors  for 




   The  question  that  arises  following  the  review  of  the  substances  released  and 
receptors  expressed  by  microglia,  is  whether  activated  microglia  contribute  to 
neurotoxicity  in  brain  injury,  inflammation  and  neurodegenerative  disease,  or 
whether  their  presence  and  activation  have  a  neuroprotective  effect.  In 







Pocock,  2007)  and  in  vivo  (Xiang  et  al.,  2006).  This  activation  is  linked  with  NO 
mediated  neurotoxicity  (Ii  et  al.,  1996;  Qin  et  al.,  2002;  Hooper  et  al.,  2009), 
indicating a toxic role for microglia in disease progression. In Parkinson’s disease 
there is generalised microglial activation, which is not limited to the degenerating 
regions  (Imamura  et  al.,  2003).  α‐synuclein  aggregates  can  be  internalised  by 
microglia in vitro and subsequent microglial activation can result in nicotinamide 
adenine dinucleotide phosphate (NADPH) oxidase mediated production of reactive 
oxygen  species  and  neurotoxicity  (Zhang  et  al.,  2005).  In  neuroinflammation, 
microglia  seem  to  play  a  dual  role,  being  involved  in  the  initial  inflammatory 
response where they act as antigen presenting and debris phagocytosing cells, but 
also  exhibiting  a  persistent  activation  phenotype  in  disease  progression.  The 
involvement of microglia in MS will be extensively discussed in 1.3.4.  


















Europe.  The  disease  is  less  frequent  in  non‐white  individuals  and  there  are 
geographical patterns to the disease with frequency of MS increasing with distance 
from the equator. The average age of MS onset is 29.2 years and it has a female 
predominance  of  approximately  2:1  (WHO  and  Multiple  Sclerosis  International 
Federation, Atlas, 2008).  
   MS can manifest a variety of neurological symptoms with certain recurring themes 
and  unpredictable  course.  The  most  common  symptoms  are  optic  neuritis, 









   The  clinical  course  of  MS  can  follow  a  varying  pattern  over  time.  Relapsing 
remitting MS (RR‐MS) accounts for 85% of all MS cases, with clearly defined relapses 
followed by full recovery (Lublin & Reingold, 1996). Over years, patients experience 
episodes  of  acute  worsening  of  neurological  function  and  develop  progressive 
disability, which is known as secondary progressive MS (SP‐MS). During the SP‐MS 
course,  lesion  activity  decreases  and  degenerative  changes  predominate  over 







was  recognised  as  an  inflammatory  process  that  was  associated  with  focal 
destruction of myelin sheaths. Indeed the oligodendrocytes are a principal target of 
the  immune  attack  in  MS,  where  cells  of  the  immune  system  release  cytotoxic 
cytokines and autoreactive antibodies that target the proteins of the myelin sheath. 
Subsequent  demyelination  of  the  nerve  axons  results  in  saltatory  conduction 
compromise, which can lead to the clinical features of MS. Partially demyelinated 
axons conduct nerve impulses at reduced velocity, while demyelinated axons can 




injury,  followed  by  partial  or  complete  recovery,  culminating  in  gliosis  and 
neurodegeneration.  Repeated  attacks  lead  to  successively  less  effective 
remyelination,  until  a  scar‐like  plaque  with  preserved  axons  set  in  a  matrix  of 
astrocytes, an MS lesion, is built up (reviewed by Lassmann et al., 2007). MS lesions 










plaque  (Prineas  et  al.,  2001).  An  inactive,  or  chronic,  demyelinated  lesion  is 
















   Another  histologically  defined  MS  lesion,  which  due  to  advances  in  imaging 








lesion  start,  as  supported  by  the  lack  of  blood‐bran  barrier  (BBB)  damage  and 
inflammation  with  specific  activation  of  microglia,  since  there  is  only  little   39 
macrophage infiltration (Gay et al., 1997). It is thus possible that demyelination has 
not  yet  occurred.  The  preactive  lesions  are  defined  as  round  or  oval  regions 
demarcated by a cluster of microglia expressing elevated levels of HLA‐DR with lack 












in  their  activation,  iNOS  expression,  NO  production  and  TNF‐α  release  (Bhat  & 
























genetic  susceptibility  for  MS  (Haines  et  al.,  1998).  The  more  recently  developed 
genome‐wide association studies identified the HLA‐DRB1 locus as a risk locus with 
very  strong  statistical  significance  and  with  65  different  single  nucleotide 




cell‐surface  glycoproteins  with  a  fundamental  role  in  immune  recognition  of  self 
from non‐self antigens. Polymorphic HLA‐DRB1 residues are associated with human 
autoimmune  disease  by  affecting  the  shape  and  charge  of  the  P4  pocket  in  the 
peptide‐binding site of the HLA molecule. For example the HLA‐DRB*1501 allele has 
a  large  hydrophobic  P4  pocket  which  favours  aromatic  residue  binding  to  the 
molecule (Smith et al., 1998). Another candidate gene associated with MS is the IL7R 
gene.  The  T244I  non‐synonymous  SNP  was  identified  in  the  IL7R  in  the  region 
encoding for one of the transmembrane domains of IL7R protein, with consequences 
for  the  function  of  the  receptor.  IL7R‐mediated  signalling  is  important  for  T 







(Byun  et  al.,  2008;  Cénit  et  al.,  2009).  With  the  development  of  high  resolution 
genomic studies more susceptibility gene association studies are expected to emerge 
in the forthcoming years.  
   Population  genetics  alone  cannot  explain  the  distribution  of  MS.  The  high 
prevalence rates in northern Europe in contrast to the low frequency rates of the 
disease in African populations, the latitude effect, or even the association of MS with 









retroviruses  and  the  bacterial  agent  Chlamydia  pneumoniae  (reviewed  by 
Giovannoni  et  al.,  2006).  EBV  is  of  special  interest  to  MS  researchers  since  it  is 
associated with a dramatic increase in MS risk, which has been obfuscated for many 
years by the fact that EBV infects more than 95% of the adult population. Individuals 
who  are  seronegative  for  EBV  are  in  very  low  risk  of  developing  MS,  a  finding 
strengthened by studies of paediatric MS (Sumaya et al., 1980; Alotaibi et al., 2004; 
Pohl  et  al.,  2006).  Furthermore,  the  risk  for  MS  is  significantly  increased  among 


















inflammatory  response,  although  additional  mechanisms  are  required  for  myelin 
sheath destruction (Lassmann et al., 1981). The initial event for the activation of 
auto‐reactive  T‐cells  remains  unclear,  although  a  ‘molecular  mimicry’  theory  has 
been  proposed,  where  common  microbes  can  activate  antigen  presenting  cells 
through the normal acquired immune response but by also expressing cell surface 






CNS  (reviewed  by  Hafler,  2004).  T  cell  infiltration  into  the  CNS  depends  on 
alterations in the expression of T cell or endothelial cell surface molecules, together 
with the secretion of enzymes that degrade the extracellular matrix (Carrithers et al., 
2000).  Within  the  CNS,  T  cells  are  re‐stimulated  by  microglia  and  macrophages 




lesions  suggest  an  important  role  for  humoral  immunity  in  MS  (reviewed  by 
Lucchinetti  et  al.,  1998;  Storch  et  al.,  1998).  Demyelination  follows  specific 
recognition  and  opsonisation  of  myelin  sheaths  by  antibodies  present  on  the 
extracellular  surface  of  myelin  membranes.  MOG  appears  to  be  an  important   43 
glycoprotein  target  for  antibody‐mediated  demyelination  (Linington  et  al.,  1988). 
The destruction of antibody‐opsonised myelin can then be mediated by complement 
(Piddlesden et al., 1993) or activated macrophages (Scolding & Compston, 1991).  




toxicity  to  oligodendrocytes  and  neurones  (reviewed  by  Probert  et  al.,  2000). 
Exposure of microglia to myelin itself can render them neurotoxic by NO, TNF‐α and 
glutamate release (Pinteaux‐Jones et al., 2008). Oligodendrocytes are traditionally 
considered  as  cells  particularly  sensitive  to  toxic  insults  such  as  cytokines, 
inflammatory  molecules,  glutamate  or  complement.  There  is  however  evidence 





    Oligodendrocyte  pathology  is  profoundly  different  between  patients  or  at 
different  stages  of  disease  progression.  This  observation  suggests  that  the 
mechanism of demyelination and oligodendrocyte damage is not uniform in MS. 
Four  different  patterns  of  demyelination  have  been  identified,  based  on  the 




demyelinating  lesions  taking  up  and  digesting  myelin  debris.  This  pattern  is  also 
characterised  by  relative  axonal  sparing  and  active  remyelination.  Pattern  II 
resembles  pattern  I  with  the  additional  presence  of  immunoglobulins  (Prineas  & 
Graham, 1981) and activated complement at the active lesions. Tissue damage and 






is  apoptotic.  These  lesions  are  characterised  by  hypoxia‐like  damage  and  the 
involvement of microglia is less pronounced (Aboul‐Enein et al., 2003). Finally, the 
less common pattern IV lesions are characterised by severe oligodendrocyte damage 
that  is  followed  by  demyelination  with  little  signs  of  remyelination.  It  has  been 
proposed  that  the  subset  of  patients  with  these  lesions  may  be  genetically 






   The  neurological  deficits  manifested  in  MS  reflect  demyelination,  impaired 






















able  to  prevent  axonal  degeneration.  Furthermore  it  was  shown  that  Na(v)1.6 
channels which are normally expressed at the nodes of Ranvier, are upregulated and 
expressed along demyelinated axons and can contribute to axonal injury because   45 
they  generate  a  more  persistent  current  than  Na(v)1.2  that  normally  exist  along 
myelinated  axons  (reviewed  by  Waxman,  2006).  NO,  which  is  released  from 
activated microglia, is present at increased concentrations in acute MS lesions and 





























issue  of  neuroprotection  in  MS  or  other  diseases  with  a  neurodegenerative 
























(Albrecht  et  al.,  2007).  Active  inflammation  was  also  shown  to  promote 
remyelination (Setzu et al., 2006). Experimental macrophage depletion in adult rats 
using  clodronate  liposomes,  which  are  toxic  when  injested  by  macrophages, 
influenced the growth factor environment, thereby affecting the behavior of OPCs 
and  hence  the  efficiency  of  remyelination  (Kotter  et  al.,  2005).  Finally,  active 















and  the  microglial  marker  CD68  were  localised  in  preactive  MS  lesions  and 
correlated  notably  with  absence  of  demyelination  and  leukocyte  infiltration  (De 






















been  implicated  with  microglial  activation  that  can  lead  to  neurotoxic  cascades 




cytokines  released  from  microglia  has  been  implicated  in  toxic  and  protective 
responses.  Following  LPS  activation,  microglia  secrete  TNF‐α  and  FasL  and  are 
neurotoxic in vitro (Taylor et al., 2005). On the other hand neuroprotective effects 
have been attributed to microglial secretion of IL‐1β (Diem et al., 2003) and IL‐23 (Li 
et  al.,  2007).  Microglia  are  also  activated  in  a  paracrine  manner  by  secreted 
cytokines. Microglial activation with IFNγ was neurotoxic in vitro (Butovsky et al., 
2006) and inhibited remyelination by inducing oligodendrocyte ER stress (Lin et al., 









is  used  in  the  diet  of  8  week  old  C57BL/6  mice.  Mature  oligodendrocytes  are 
specifically insulted since they cannot fulfil the metabolic demand of supporting vast 








     During  the  chronic,  degenerative  stages  of  MS,  microglial  activation  has  been 
attributed  to  a  number  of  factors  that  persist  in  the  chronic  lesions.  BBPs  are 
potential microglial activators. Albumin has been found to activate microglia in vitro   49 
and induce calcium response (Hooper et al. 2005; 2009a). Fibrinogen has also been 
implication  in  microglial  activation  by  causing  proliferation  and  changes  in 








BBB  disruption  in  MS  (Yamauchi  et  al.,  2007).  On  the  other  hand,  beneficial 
immunomodulatory  effects  in  MS  have  been  attributed  to  NO,  so  there  is  still 
controversy over its role in MS (reviewed by Smith & Lassmann, 2002). To further 
support the neurodegenerative role of activated microglia in progressive, chronic 
MS,  activated  phagocytic  microglia  were  immunohistochemically  located  at  the 
margins  of  demyelinated  cortical  regions  (Gray  et  al.,  2008).  Previously,  direct 
microglial  interaction  with  oligodendrocytes  was  demonstrated  at  the  edges  of 
chronic demyelinating lesions (Peterson et al., 2002). 














studying  the  interactions  of  two  cell  populations  may  lead  to  interesting 
observations regarding disease pathology. 
   It was initially documented that although ramified microglia show little contact 





exposed  to  it  for  a  prolonged  time  period  (96  hours;  McLaurin  et  al.,  1995).  In 




was  also  found  to  protect  TNF‐α  induced  OPC  injury  by  interrupting  the  OPC 
mitochondrial apoptotic pathway (Pang et al., 2007).  In a hypoxic rat model, TNF‐α 











   It  is  strongly  suggested  that  non‐activated  microglial  conditioned  medium 
promotes  OPC  survival  and  maturation  into  oligodendrocytes  (Pang  et  al.,  2000; 
Nicholas et al., 2001;  Miller et al., 2007). When microglia are activated with LPS, it 
has been proposed that LPS activation does not only abolish the protective effect of 
microglial  conditioned  medium  on  OPCs,  but  furthermore  when  LPS  activated 
microglial conditioned medium is added to OPC cultures, it induces OPC death (Pang   51 
et  al.,  2000).  This  is  also  true  for  co‐cultures  of  microglia  and  immature 
oligodendrocytes (Li et al., 2008). The effect of LPS on OPCs was shown not to be cell 
autonomous  but  mediated  through  activation  of  microglial  cells  via  the  TLR4 
receptor  (Lehnardt  et  al.,  2002).  The  same  study  also  determined  that  only  LPS 
activated  microglia  and  not  astrocytes  or  fibroblasts  significantly  mediated  OPC 
death when grown in Boyden chambers (chambers that allow separate culture of the 





   Quiescent  microglial  conditioned  medium  was  shown  to  enhance  mature 
oligodendrocyte  survival  (Pang  et  al.,  2000).    LPS  activated  microglia  were  also 
shown  to  be  beneficial  for  cell  survival  when  co‐cultured  with  mature 
oligodendrocytes (Miller et al., 2007). In a different study, LPS activated microglia co‐
cultured  with  mature  oligodendrocytes  for  48  hours  were  found  to  induce 












   In  an  early  study  the  effect  of  the  NO  donor  SNAP  on  glia  was  measured  by 








alone  was  unlikely  to  induce  oligodendrocyte  toxicity,  whereas  its  by‐product 
peroxynitrite was toxic to MAG positive oligodendrocytes (Jack et al., 2007).  In a rat 
cell culture study peroxynitrite was found responsible for LPS mediated cell death of 
immature  oligodendrocytes  when  co‐cultured  with  microglia  (Li  et  al.,  2005). 
Interestingly, it was later shown that in mixed cell cultures where astrocytes were 
also  present,  inhibition  of  iNOS  or  peroxynitrite  decomposition  catalysis  did  not 




in  Table  1.3.5.1.  It  may  be  possible  that  astrocytes  protect  against  peroxynitrite 
toxicity  due  to  their  high  antioxidative  capacities  (Peuchen  et  al.,  1997).  It  was 









is  an  antibiotic  that  prevents  oligodendrocyte  death  by  inhibiting  microglial  p38 
mitogen‐activated protein kinase (MAPK) phosphorylation, RhoA activation and p75 
neurotrophin receptor expression after spinal cord injury (Yune et al., 2007). In the 
cuprizone  model  of  demyelination,  inhibition  of  microglial  activation  with 




microglia  and  oligodendrocytes  depend  on  the  microglial  activation  state,  the 








































The  NO  donors  dipropylenetriamine‐NONOate  (DPT/NO),  diethylaminetriamine‐
NONOate (DETA/NO), S‐nitroso‐N‐acetylpenicillamine (SNAP) sodium nitroprusside 
(SNP)  or  peroxynitrite  (ONOO











hyaluronan  which  accumulates  in  demyelinated  MS  lesions  and  inhibits  OPC 
maturation (Back et al., 2005). Astrocytes also express molecules that inhibit axonal 



















lesions  (Stadelmann  et  al.,  2002).  It  has  been  proposed  that  astrocytes  are 
implicated in the postulated neuroprotective effect of TNF‐α in MS by expressing 
BDNF  in  a  TNF‐α  dependent  manner  (Saha  et  al.,  2006).  In  human  MS  tissue 
astrocytes were shown to express MHC class I (Höftberger et al., 2004) and class II 
(Zeinstra  et  al.,  2000)  although  other  studies  showed  absence  of  MHC  class  II 
expression  in  astrocytes  (Bö  et  al.  1994;  Höftberger  et  al.,  2004).  IL‐12,  IL‐23 
(Constantinescu et al., 2005) and IL‐17 (Tzartos et al., 2008) are also secreted by 
astrocytes, supporting their involvement in T cell presentation and activation.    55 
   Astrocytes  are  implicated  in  MS  not  only  by  forming  the  glial  scar  but  also  by 
expressing growth factors and cytokines, as well as responding to such molecules in 
a paracrine manner. They take active part in the molecular concert that mediates the 
immune  response  and  the  lesion  formation  in  MS  and  the  balance  of  secreted 
molecules  determines  if  a  toxic  of  protective  phenotype  will  prevail.  The 













trans‐endothelial  migration  (reviewed  by  Weiss  et  al.,  2009).  Important  for  the 
recognition  and  adhesion  of  leukocytes  are  the  endothelial  adhesion  molecules 
inter‐cellular adhesion molecule‐1 (ICAM‐1), VCAM‐1  (Oppenheimer‐Marks et al., 













shown  that  src‐suppressed  C‐kinase  substrate  (SSeCKS)  stimulated  expression  of 




























endothelial  cells  during  relapses  has  also  been  reported  (van  der  Maesen  et  al., 
1999),  although  endothelial  cell  class  II  MHC  expression  has  been  discounted  by 
other studies (Bö et al., 1994; Ulvestad et al., 1994).   58 
   There is a large amount of data showing altered levels of endothelial proteins in 
MS.  It  is  suggested  that  endothelial  cells  are  activated  by  cytokines  released  by 
leukocytes  and  in  active  MS  lesions  molecules  promoting  trans‐endothelial 











patients.  The  effect  of  NO  release  in  MS  lesions  is  still  unclear  because  NO 
production  has  been  implicated  in  both  toxic  and  protective  processes.  eNOS 
expressed  by  endothelial  cells  induces  vasodilation,  while  iNOS  expressed  by 
microglia and macrophages in response to stress produces NO. NO can form reactive 


















to  trans‐endothelial  migration  can  be  limited  in  inflammatory  and 










2009).  The  transient  BBB  ‘opening’  is  achieved  by  intracarotid  infusions  of 











two  types  of  receptors,  the  ionotropic  glutamate  receptors  (iGluRs)  and  the 
metabotropic glutamate receptors (mGluRs). The iGluRs are multimeric ligand gated 
ion  channels  that  allow  ions  such  as  Na
+  and  Ca
2+  to  enter  the  cell.  iGluRs  are 
subdivided  into  three  groups,  N‐methyl‐D‐aspartic  acid  (NMDA)  receptors,  alpha‐
amino‐3‐hydroxy‐5‐methyl‐4‐isoxazolepropionic acid (AMPA) receptors and kainate 
(KA)  receptors  (reviewed  by  Tikhonov  &  Magazanik,  2009).  The  mGluRs  are 
metabotropic  receptors  that  couple  to  G‐proteins  to  modulate  slow  synaptic 
transmission  through  intracellular  second  messengers.  Thus  far,  eight  different 
mGluR receptors have been identified, mGluR1 to mGluR8. mGluR receptors have 
been classified into three different groups (groups I‐III) based on their sequence 
similarity,  pharmacological  properties  and  signal  transduction  mechanisms 
(reviewed  by  Benarroch,  2008).  Group  I  consists  of  the  mGluR1  and  mGluR5 
receptors. Group I receptors are coupled to phospholipase C and subsequently to 
the  hydrolysis  of  phosphatidylinositol  into  inositol  triphosphate  (IP3)  and 
diacylglycerol  (DAG),  leading  to  intracellular  Ca
2+  release  and  PKC  activation 
respectively.  Group  II  consists  of  the  mGluR2  and  mGluR3  receptors.  Group  II 
receptors are negatively coupled to the cyclic adenosine monophosphate (cAMP) 
cascade in the cell. Group III consists of the mGluR4, mGluR6, mGluR7 and mGluR8 
receptors.  Group  III  receptors  are  also  negatively  coupled  to  adenyl  cyclase 



























































stimulation  of  group  III  mGluRs  reduces  microglial  reactivity  and  neurotoxicity 
(Taylor  et  al.,  2003).  These  data  demonstrate  that  it  is  likely  that  strategies 
regulating  specific  mGluR  activation  may  have  a  therapeutic  effect  in 
neurodegenerative disease where microglial activation is involved.  
   Activation  of  microglia  with  LPS,  amyloid  β  or  CGA  peptide,  all  expressed  in 
Alzheimer’s plaques, caused microglial glutamate release and resulted in a feedback 
activation of group II mGluRs, thus fuelling microglial neurotoxicity (Taylor et al., 




receptors  can  be  neuroprotective  following  LPS,  CGA  or  amyloid  β  microglial 
activation (Taylor et al., 2003), group III mGluRs offer further targets for controlling 
microglial toxicity in neurodegenerative disease (reviewed by Pocock & Kettenmann, 
2007).  It  was  also  shown  that  treatment  with  group  I  receptor  mGluR5  agonists 





    mGluR  receptors  are  recognised  as  promising  therapeutic  targets  for  many 
neurological  diseases  where  glutamatergic  disturbance  is  evident  (reviewed  by 
Marek,  2004).  Drugs  acting  at  mGluR  receptors  can  regulate  the  glutamatergic 
system  without  affecting  the  normal  synaptic  transmission.  In  MS  patients, 
glutamate levels in the CSF are elevated during relapses or in patients with severe 
neurological defect (Stover et al., 1997; Barkhatova et al., 1998). Glutaminase, the 





   Immunohistochemical  staining  of  active  MS  lesions  revealed  upregulation  of 






Group  II  receptors  were  stained  in  astrocytes  and  bipolar  cells  that  the  authors 
speculated  were  OPCs  (Newcombe  et  al.,  2008).  Microglial  mGluRs  can  induce   64 
toxicity  or  neuroprotection  (see  1.5.2)  and  it  can  be  speculated  that  group  II 
microglial and astrocyte receptor activation in acute lesions is triggered by elevated 
gluatamate  levels,  thus  contributing  to  microglial  toxicity.  On  the  other  hand 
upregulation  of  astrocytic  mGluR4  and  mGluR8  receptors  at  the  rim  of  the  MS 
lesions  might  indicate  high  levels  of  glutamate,  activating  group  III  mGluRs  in 





















  Establish  an  in  vitro  model  for  the  study  of  microglial‐oligodendrocyte 
interactions by culturing the cell populations separately or in contact. 
  Examine LPS and BBPs as potential microglial activators in MS and elucidate 
the  intracellular  pathways  that  lead  to  microglial  activation  and  cytokine 
release. 













microglial  activation  or  by  blockade  of  oligodendrocyte  intracellular  pathways. 
Manipulation  of  cells  and  modulation  of  molecular  pathways  that  prevent 
oligodendrocyte maturation or promote cell death can lead to novel strategies to 




























of  Bristol,  School  of  Medical  Sciences,  Bristol,  UK).  Foetal  bovine  serum  (FBS), 
Dulbecco's  Modified  Eagle's  Medium  (DMEM)  powder  (52100‐039),  Minimum 
Essential  Medium  (MEM)  powder  (11700‐077),  fungizone  (15290026)  and  Trizol 
reagent (15596018) were obtained from Invitrogen (Paisley, UK). Earle’s balanced 








N'‐tetramethylethylenediamine  (TEMED,  20‐3000‐25)  were  obtained  from  Severn 
Biotech (Worcestershire, UK). ECL Plus Western Blotting Reagents (RPN2106) and 
Amersham  Hyperfilm  ECL  (28‐9068‐37)  were  purchased  from  GE  Healthcare 
(Buckinghamshire, UK). The antibodies rabbit anti‐NG2 (sc‐20162), goat anti‐COX‐2 
(sc‐1746), goat anti‐GFAP (sc‐6171) donkey anti‐goat‐IgG (sc‐2056), goat anti‐rabbit‐
IgG  (sc‐2004)  were  purchased  from  Santa  Cruz  Biotechnology  (Heidelberg, 
Germany).  Donkey  anti‐mouse‐IgG  antibody  was  purchased  from  Affinity 
Bioreagents (Cambridge, UK). Mouse anti‐ED1 (MCA341) and mouse anti‐CD11b (OX‐
42, MCA275EL) antibodies were obtained from Serotec (Oxford, UK). Rabbit anti‐







0652),  2‐Amino‐5,6‐dihydro‐6‐methyl‐4H‐1,3‐thiazine  hydrochloride  (AMT‐HCl, 
0871),    (S)‐3,5‐Dihydroxyphenylglycine  (DHPG,  0805),    (RS)‐1‐Aminoindan‐1,5‐
dicarboxylic acid (AIDA, 0904), 6‐Methyl‐2‐(phenylazo)‐3‐pyridinol (SIB‐1757, 1215), 
(2S,2'R,3'R)‐2‐(2',3'‐Dicarboxycyclopropyl)  glycine  (DCGIV,  0975),  (RS)‐1‐Amino‐5‐
phosphonoindan‐1‐carboxylic acid (APICA, 1073), L‐(+)‐2‐Amino‐4‐phosphonobutyric 
acid (L‐AP4, 0103), (RS)‐4‐Phosphonophenylglycine (RSPPG, 1220) and (S)‐2‐Amino‐2‐
methyl‐4‐phosphonobutanoic  acid  (MAP4,  0711)  were  purchased  from  Tocris 
(Bristol, UK). TNF‐α Quantikine ELISA kit (#RTA00) was purchased from R&D Systems 
(Oxford, UK). Fibroblast growth factor (bFGF, 100‐18B) and platelet‐derived growth 















(2‐hydroxyethyl)‐1‐piperazineethanesulfonic  acid  (HEPES,  H0891),  ampicillin 










10%  foetal  bovine  serum  (FBS)  supplemented  with  2  mM  glutamine,  100  U/ml 
penicillin and 100 mg/ml streptomycin at 37
oC in 6% CO2. BV‐2 cells were harvested 
with  accutase  (Invitrogen),  which  was  then  neutralized  with  an  equal  volume  of 
medium. The cells were centrifuged at 3645 g for 5 minutes at 19
oC (Eppendorf 
Centrifuge  5804R),  resuspended  in  fresh  warm  medium  and  seeded  into  a  new 






























Cell  Signalling  Laboratory,  Institute  of  Neurology,  UCL.  Modified  Sato  medium 
consisted of Dulbecco's modified Eagle's medium (DMEM), 0.1% (w/v) bovine serum 
albumin  fraction  V,  60 µg/L  progesterone,  16.1 mg/L  putrescine,  5 µg/L  sodium 
selenite, 400 µg/L tri‐iodothyronine, 400 µg/L l‐thyroxine, 50 mg/L holo‐transferrin, 




















eventually  died.  They  also  should  not  be  split  too  sparse  because  that  delayed 



































    5‐6  day  old  Sprague‐Dawley  rat  pups  were  killed  by  cervical  dislocation  and 
decapitation in accordance with the United Kingdom Animals (Scientific Procedures) 
Act,  1986.    Brains  were  quickly  removed  and  placed  into  a  sterile  petri  dish 
containing  minimum  essential  medium  (MEM)  with  25  mM  4‐(2‐hydroxyethyl)‐1‐

















glial  cultures  were  ready  to  shake  and  differentially  dissociate  the  different  cell 
populations.    73 
   If primary mixed glial cultures were desired, the cells were initially seeded directly 






























while  OPCs  only  loosely  adhered.  The  medium  was  then  gently  aspirated  and 
expelled 4 or 5 times to remove any loosely adhered OPCs from the Petri dish. The 








for  approximately  20  minutes.  After  20  minutes  400ml  of  defined  serum  free 
medium  were  gently  added  in  each  well.  The  defined  medium  used  to  culture 
oligodendrocytes  consisted  of  DMEM  (with  NaHCO3),  0.1%  BSA,  1mM  sodium 
pyruvate,  5  μg/ml  insulin,  50  μg/ml  transferrin,  30  nM  selenium,  400  μg/ml  tri‐
iodothyronine  (T3),  5  ng/ml  biotin,  10  nM  hydrocortisone,  0.5%  FBS,  25  μg/ml 
gentamycin,  100  U/ml  penicillin  and  100  mg/ml  streptomycin.  The  medium  was 
changed after 24 hours and from then on every 2 days. FBS could be increased to 2% 









































at  100  g  x  5  minutes.  The  soft  pellet  was  then  resuspended  in  1  ml  of  culture 
medium  consisting  of  minimum  essential  medium  (MEM)  with  NaHCO3,  30  mM 
glucose, 1 mM glutamine, 10% FCS, 100 U/ml penicillin, 100 μg/ml streptomycin and 
6 μg/ml ampicilin. The volume of the suspension was adjusted and cells were plated 












before  use.  Before  activating  the  cells,  the  medium  was  changed  to  serum  free 
medium and cells were left for at least 2 hours before activation. Microglia or BV‐2s 

































2‐Amino‐5,6‐dihydro‐6‐methyl‐4H‐1,3‐thiazine  hydrochloride  (AMT‐HCl),  Y‐27632, 




(S)‐3,5‐dihydroxyphenylglycine  (DHPG),  (RS)‐1‐aminoindan‐1,5‐dicarboxylic  acid 
(AIDA),  6‐methyl‐2‐(phenylazo)‐3‐pyridinol  (SIB‐1757),  (2S,2'R,3'R)‐2‐(2',3'‐
dicarboxycyclopropyl)  glycine  (DCGIV),  N‐acetylaspartylglutamate  (NAAG),  (RS)‐1‐
amino‐5‐phosphonoindan‐1‐carboxylic  acid  (APICA),  L‐(+)‐2‐amino‐4‐
phosphonobutyric acid (L‐AP4), (RS)‐4‐phosphonophenylglycine (RSPPG) and (S)‐2‐
amino‐2‐methyl‐4‐phosphonobutanoic  acid  (MAP4)  were  administered  to  primary 
cell cultures at concentrations based on previous studies on the effect of mGluR 
manipulation on microglia (Taylor et al., 2002; 2003; 2005). 
Compound  Description  Concentration  Catalogue No. 
LPS  Prototype microglial activator  0.1‐0.5 μg/ml  Sigma L2762 
FV albumin  Microglial activator  1 mg/ml  Sigma A6272 
FG  Microglial activator  2.5 mg/ml  Sigma F4883 
FN  Microglial activator  1 mg/ml  Sigma F5386 
Thal  TNF‐α synthesis inhibitor  3 ‐ 10 μg/ml  Tocris # 0652 
AMT‐HCl  iNOS inhibitor  1 ‐ 3 mM  Tocris # 0871 
Y‐27632  ROCK inhibitor  50 mM  Calbiochem 688000 
Anti‐TLR4  TLR‐4 blocking antibody  3 μg/ml  Santa Cruz sc‐13591 L 
Anti‐CD11b  CD11b blocking antibody  10 μg/ml  Serotec MCA27EL  
Compound  Description  Concentration  Catalogue No. 
DHPG  Group I mGluR agonist  100 mM  Tocris # 0805 
AIDA  Group I mGluR antgonist  250 mM  Tocris # 0904 
SIB‐1757  mGlu5 antagonist  50 mM  Tocris # 1215 
DCGIV  Group II mGluR agonist  500 nM  Tocris # 0975 
NAAG  mGlu3 agonist  50 mM  Sigma A5930 
APICA  Group II antagonist   200 μM  Tocris # 1073 
L‐AP4  Group III mGluR agonist  100 mM  Tocris # 0103 
RSPPG  Group III mGluR agonist  100 mM  Tocris # 1220 
MAP4  Group III mGluR antagonist  500 mM  Tocris # 0711   78 
   For  the  line  of  experiments  where  interactions  between  primary  microglia  and 
oligodendrocytes  were  studied,  oligodendrocytes  were  treated  with  microglial 
conditioned medium as described above, or the two cell populations were cultured 







restricted  into  their  compartments  without  physical  contact.  The  same  set  of 







To  study  primary  microglial  (MG)  ‐  oligodendrocyte  (OL)  interactions,  microglial 











   Live‐dead  cell  staining  was  performed  on  primary  microglia,  primary 
oligodendrocyte lineage cells, co‐cultures, CGCs, as well as on BV‐2s or CG‐4s. The 
fluorescent  nuclear  dyes  2´‐(4‐Ethoxyphenyl)‐5‐(4‐methyl‐1‐piperazinyl)‐2,5´‐bi‐1H 
benzimidazole  (Hoechst  33342)  and  propidium  iodide  (PI)  were  utilised.  Hoechst 
33342 is a membrane permeable dye that binds to all nuclei by binding to the minor 







apoptosis  (Crissman  et  al.,  1976).  The  percentage  of  red  stained  cells  in  a  cell 
population  was  thus  the  percentage  of  dead  cells  in  the  cell  population.  When 
studying co‐cultures containing microglia, cells were also stained with 2 μg/ml FITC 
conjugated  Bandeiraea  simplicifolia  isolectin  B4  (BSI‐B4).  BSI‐B4  is  a  lectin  with 
exclusive affinity for the α‐D‐galactosyl oligosaccharide residue (Wood et al. 1979) 
and it selectively binds to microglia in the brain (Streit & Kreutzberg 1987). FITC 













calculated  separately,  so  the  differential  effect  of  treatments  to  microglia  and 
oligodendrocytes could be assessed. 














also  incubated  with  1  mg/ml  FITC  conjugated  albumin  for  60  minutes  at  4
oC  to 
prevent internalisation and to ensure that the observed fluorescence was not due to 
surface  binding  (Tabernero  et  al.,  1999;  Hooper,  2003;  Pinteaux‐Jones,  2007). 
Microglia were then washed one time in PBS to remove any FITC conjugated albumin 
remaining in the media and were viewed under the  microscope on a slide with basic 
medium  (3  mM  NaCl,  3.5  mM  KCl,  0.4  mM  KH2PO4,  20  mM  N‐
tris(hydroxymethyl)methyl‐2‐aminoethanesulphonic  acid,  1.2  mM  Na2SO4  and  1.3 
mM  CaCl2  at  pH  7.4)  as  in  2.5.1.  Cells  were  viewed  at  excitation  343  nm  with 
emission 480 nm for Hoechst 33342 and at excitation 495 nm with emission 517 nm 
for FITC conjugated albumin. Images of 3 or 4 fields per coverslip were captured 

































   The  cells  were  viewed  under  a  fluorescence  microscope  (Zeiss  Axioskop  2, 


























































   Western  blotting  is  an  electrophoretic  method  used  for  separating  proteins 
present in a biological sample and successfully identifying the presence of a specific 
















   Primary  microglia,  BV‐2  cells  or  oligodendrocytes  (200,000  cells/well)  were 
harvested into 30 μl of lysis buffer. The formulation of the lysis buffer aimed at lysing 
the  cells  and  solubilising  the  membranes  as  well  as  preserving  the  state  of  the 








































polyacrylamide  gels  (SDS  PAGE).  Two  glass  plates  were  assembled  together, 
separated by spacers and mounted onto a pouring stand. Resolver and stacker gel 
composition  is  listed  in  Table  2.7.3.1.  N,  N,  N',  N'‐tetramethylethylenediamine 
(TEMED)  and  ammonium  persulfate  (APS),  both  required  for  acrylamide 
polymerisation and gel formation, were added last just before pouring. Depending 
on  the  molecular  weight  of  the  protein  under  investigation,  the  percentage  of 
acrylamide  in  the  resolver  gel  could  be  adjusted,  with  higher  percentage  of 













































Rad  Presision  Plus  Protein  standards  #161‐0373,  Hertfordshire,  UK,  Magic  Mark, 
Invitrogen, Paisley, UK) were also added into wells. The tank was then filled with 
running buffer and the gels were electrophoressed at 120‐130V until the proteins 




glycine,  20%  methanol,  0.01%  SDS).  While  the  gel  was  equilibrating,  a  piece  of 
polyvinylidene fluoride (PVDF) membrane (Immobilon P) the same size as the gel 
was activated in ice cold methanol for 1 minute, followed by 5 minutes in distilled 















buffer  saline  (TTBS:  10  mM  Tris  HCl,  150  mM  NaCl,  0.5%  Tween‐20,  pH  7.4). 
Subsequently  the  membrane  was  blocked  for  non‐specific  binding  into  blocking 
buffer (5% non‐fat dried milk in TTBS, unless otherwise specified) for at least one 
hour  with  shaking.  The  next  step  was  to  incubate  the  PVDF  membrane  with  an 
appropriate primary antibody diluted in blocking buffer for the time specified (Table 





of  solution  2  of  ECL  (Amersham  Biosciences)  for  1  minute.  Subsequently  the 
membrane  was  drained  between  two  sheets  of  3MM  paper  sheet,  wrapped  in 
transparent wrap film (Saran) and fixed on an X‐ray film cassette. In a darkroom the 





otherwise  stated,  so  blots  presented  in  this  study  are  representative  of  three 
experiments. 
   The blots could be reprobed for a different protein of interest.  For this purpose, 
















































(Xaus  et  al.,  2000).  Sandwich  ELISA  is  a  variant  of  the  ELISA  technique  where  a 











with  wash  buffer.  100  μl  of  rat  anti‐TNF‐α  polyclonal  antibody  conjugated  to 
horseradish peroxidise (TNF‐α conjugate) were then added for a 2 hour incubation at 
room temperature. After four washes with wash buffer 100 μl of substrate solution 
were  added  to  the  wells  for  30  minutes  in  the  dark  (colour  reaction).    After  30 
minutes 100 μl of hydrochloric acid solution (stop solution) were added to terminate 


























   Following  concerns  over  the  purity  of  commercially  available  plasma‐derived 
proteins  used  to  activate  microglia  and  the  possibility  that  they  might  be 
contaminated  with  LPS  (Weinstein  et  al.,  2008),  an  endotoxin  quantification  kit 






for  endotoxin.  The  reaction  consists  of  a  cascade  of  enzyme  activation  steps 
terminating  in  the  cleavage  of  the  peptide  coagulogen  and  the  formation  of 
insoluble coagulin, which forms a gel‐clot. This interaction forms the basis of the 




   The  method  used  was  an  endpoint  chromogenic  method  that  measured  the 
amount  of  pNA  produced  following  a  fixed  incubation  period.  Following  the 







samples,  a  standard  curve  was  constructed  by  serial  dilutions  of  50  endotoxin 



















   All  experiments  were  performed  in  triplicate  unless  otherwise  stated.  In 
microscopy experiments, cells were counted on three coverslips (4 fields of view 
counted per coverslip) per treatment from three independent experiments. Data 
were  expressed  as  a  percentage  of  the  total  number  of  cells  counted  per  field. 
Therefore the experimental data presented in this study were subjected to statistical 
analysis to compare treatments to control groups.  To compare a single treatment 



















and  characteristics  (see  1.1).  Their  connections  and  communication  contribute 
towards tissue homeostasis and function, but when studying the unique properties 
of each cell population and the interactions between them, it is essential to culture 





Combs,  2007),  but  when  attempting  to  individually  culture  cell  populations,  the 
demands are greater and the cell viability falls rapidly with cell population purity. 




2002)  and  promotes  stem  cell  differentiation  into  neurones  (Song  et  al.,  2002). 
Oligodendrocyte  death  in  vitro  is  attenuated  in  the  presence  of  astrocytes  that 
interact with oligodendrocyte membrane integrins (Corley et al., 2001). 


















































B4  (BSI‐B4).  BSI‐B4  is  a  lectin  with  exclusive  affinity  for  the  α‐D‐galactosyl 
oligosaccharide residue (Wood et al., 1979) and it selectively binds to microglia in 
the  brain  (Streit  &  Kreutzberg,  1987).  Microglia  labelled  with  BSI‐B4  were  also 
stained with Hoechst 33342 (Hoechst) which is a nuclear stain and propidium iodide 
(PI) which is a DNA stain that is membrane impermeable and can only stain dead 
cells.  The  cells  were  viewed  under  a  fluorescence  microscope  (Zeiss  Axioskop  2, 
Oberkochen,  Germany)  using  the  appropriate  filter  for  each  fluorochrome.  Cells 
were viewed at excitation 343 nm with emission 480 nm for Hoechst 33342 and at 
excitation 495 nm with emission 517 nm for FITC conjugated BSI‐B4. Images were 














OX‐42  is  a  macrophage  specific  marker  that  recognises  the  CR3  complement 
















































captured  through  the  FITC  channel.  The  second  column  shows  nuclear  staining 
(Hoechst) over‐layed on the first column. The third column depicts negative control 
images captured through the FITC or TRITC channel without the use of primary and 
FITC  conjugated  antibodies.  Microglia  exhibit  intense  vesicular  structure 
autofluorescence which can be seen in negative (–ve) FITC images where both the 











Microglial  or  astrocyte  ‐  olgodendrocyte  lysates  were  left  untreated  or  were 
activated for 24 hours with 0.1 μg/ml LPS. The cells were lysed and western blotting 
for the expression of iNOS or GFAP in the lysates was performed. Western blotting 
was  performed  to  assess  whether  these  cell  fractions  expressed  inducible  nitric 









microglial  fraction  predominantly  expressed  iNOS  following  activation  (Figure 
3.2.3.3; Saura, 2007).  
     With this method a number of microglia remained onto the astrocyte layer and 
could  be  removed  with  a  second  shake,  but  that  was  avoided  to  ensure  cell 


















Adalid  et  al.,  1996).  Another  method  that  ensures  cell  preparation  purity  is  the 












serum  develop  into  type  2  astrocytes,  cells  that  express  both  astrocyte  and 
oligodendrocyte  markers,  whilst  they  acquire  a  stellate  morphology  (Raff  et  al., 
1983).  Thus,  different  defined  medium  formulations  have  been  used  to  provide 




day  6  in  vitro,  when  cells  had  successfully  differentiated  and  MBP  was  amply 
detected,  around  40%  of  the  cells  had  died.  To  promote  cell  survival  the  media 
formulations tried were combined (oligodendrocyte medium, Table 3.3.2.1) and cell 
death at 6 DIV was reduced to approximately 23% (Figure 3.3.2.1). Cell survival could 

















































Death  levels  of  maturing  OPCs  in  vitro  were  assessed  by  staining  the  cells  with 
Hoechst (blue) and PI (red).  Hoechst and PI images alone or with bright field from 
each  day  in  vitro  (A)  (1‐4)  DIV  and  (B)  (5‐6)  DIV  are  shown.  3  coverslips  were 
assessed  per  condition  and  at  least  3  pictures  were  taken  per  coverslip.  The 
percentage of dead cells (PI) was counted in each field. At 6 DIV 23.41% of the cells 






plated  onto  PDL  coated  glass  coverslips.  After  a  week  in  culture  a  confluent 
monolayer of astrocytes had formed, on which the microglia and OPCs developed. At 
9‐12 DIV clumps of OPCs could be viewed on the astrocyte layer (Figure 3.3.2.2). 
These  cells  stained  for  the  OPC  marker  NG2.  NG2  is  a  chondroitin  sulfate 
proteoglycan, which is expressed on the cell surface of immature progenitor cells 
such as OPCs (Stallcup & Beasley, 1987; Levine et al., 1993). 12 DIV was the time 
selected  to  shake  the  mixed  glial  cultures  and  obtain  pure  microglia  and 




constituent  protein  of  myelin  and  is  present  in  differentiated,  myelinating 
oligodendrocytes (Figure 3.3.2.2). At 20 DIV (time point that would correspond to 8 





















coverslips  of  mixed  glia  at  different  time  points.  Cells  were  stained  with  OX‐42 
(green) for microglia and DAPI (blue) to stain all nuclei, and with the OPC marker 












the  6  DIV  oligodendrocyte  culture  purity  were  assessed,  even  though  the  latter 
resulted from OPC maturation. Both culture time point preparation purities were 
assessed  to  ensure  that  contaminating  cells  did  not  proliferate  during  the 
maturation period and that OPCs only differentiated into oligodendrocytes. Fixed 








at  least  three  coverslips  were  viewed  and  at  least  four  fields  were  counted  per 





























































   We  show  here  that  pure  OPCs  (93.8%  +/‐  1.3;  SEM)  and  mature  6  DIV 
oligodendrocytes  (91.9  +/‐  0.7;  SEM)  can  be  obtained  by  controlled  agitation  of 
mixed  glial  cultures  (Table  3.5.1  A).  The  slightly  lower  percentage  of  mature 
oligodendrocytes in culture most possibly reflects the increase in oligodendrocyte 
death  after  6  DIV,  with  contaminating  microglia  or  astrocyte  numbers  not  being 
affected. The physiological properties of oligodendrocyte lineage cells change with 







   To  study  interactions  between  microglia  and  oligodendrocytes,  the  two  cell 
















(SEM).  Representative  images  of  co‐cultures  of  microglia  with  OPCs  or  6  DIV 
oligodendrocytes are shown in Figure 3.3.2.5. 
   The  co‐cultures  were  initially  approximately  3:2  MG/OPCs  and  after 




at  approximately  2:3  in  the  rat  corpus  callosum  (Miller  et  al.,  2007).  Thus,  the 


















   Collectively,  for  the  study  of  the  interactions  between  microglia  and 
oligodendrocytes, a method for the isolation of pure microglia, OPCs and mature 
oligodendrocytes from 5 day old Sprague Dawley rats was developed. This method 
allowed  for  the  best  use  of  most  brain  tissue  from  each  animal  sacrificed  (the 
cerebellum was also utilised for cerebellar granule cell culture). The main advantage 
of this method is that it is an easy and efficient method that produces sufficient 




















Microglia ‐ OPCs  52.9 +/‐ 1.9  41 +/‐ 1.6  1.4 +/‐ 0.2 




(A)  Table  of  the  purity  of  microglial,  OPC  and  6  DIV  oligodendrocyte  (6  DIV  OL) 



























































persist  in  active  MS  lesions  in  an  activated  state  (Lassmann,  2003)  and  produce 







the  prototypical  pathogen‐associated  molecular  pattern  (PAMP)  and  it  induces  a 
strong immune response (Poltorak et al., 1998; Reimer et al., 2008). LPS binds the   120 
CD14/TLR4/MD2  receptor  complex,  which  promotes  the  secretion  of  pro‐
inflammatory  cytokines  in  macrophages  and  microglia.  LPS  is  widely  used 
experimentally to induce microglial activation. Microglial activation in vitro results in 
changes in cell morphology (amoeboid rather than ramified), proliferation, migration 















exposed  axons  during  the  remitting  stage  of  MS.  However,  remyelination 



















   Myelinating  oligodendrocytes  are  a  principal  target  of  the  immune  attack  in 
multiple sclerosis (reviewed by Compston and Coles, 2002). Infiltrating macrophages 
release  cytotoxic  cytokines,  while  autoreactive  antibodies  target  proteins  of  the 
myelin  sheath  such  as  MOG,  MBP,  MAG  and  PLP.  It  is  an  interesting  question 






mature  oligodendrocyte  survival  (Miller  et  al.,  2007).  Thus,  the  effect  of  LPS 
activated microglia on mature oligodendrocytes cultured in vitro was investigated. 




   Glutamate  is  implicated  in  inducing  excitotoxic  death  to  all  iGluR  expressing 





and  the  results  were  compared  with  the  effect  of  glutamate  on  microglia  and 



















































A.  Representative  fluorescence  microscopy  images  of  fixed  primary  microglia  in 
culture.  (i)  in  control,  (ii)  in  cells  activated  with  0.1  μg/ml  LPS  for  24  hours,  (iii) 
negative control (primary antibody omitted). Nuclei were stained blue with DAPI and 
the  cytoplasm  was  stained  red  with  anti‐iNOS  antibody.  Scale  bar  =  20  μm.  B. 













stain  microglia  green  (Streit  and  Kreutzberg,  1987)  and  allow  them  to  be 
distinguished  from  OPCs  when  counting  the  cells.  The  experimental  rationale  is 
depicted in Figure 2.4.1.  
   OPCs were initially treated with direct administration of LPS to study whether LPS 
was  directly  toxic  to  OPCs.  LPS  was  not  toxic  to  OPCs  in  vitro  (Figure  4.3.1  A). 
Subsequently untreated or LPS treated serum‐free MGCM was added to OPCs at a 
1:1  ratio  to  oligodendrocyte  culture  media.  MGCM  was  not  toxic  to  OPCs.  LPS 













Untreated  microglia  did  promote  OPC  survival,  although  not  significantly  (Figure 
4.3.3). LPS activated microglia did induce a small but statistically significant elevation 
of OPC cell death when compared with non‐treated microglia (Figure 4.3.3).    126 





This  microglial‐induced  OPC  death  was  attenuated  by  the  selective  inhibitor  of 
tumour  necrosis  factor  α  (TNF‐α)  synthesis,  thalidomide  (Thal)  (Peterson  et  al., 
1995). Thal suppresses TNF‐α production by accelerating the degradation of TNF‐α 
mRNA transcripts (Moreira et al., 1993). Thal inhibits TNF‐α and IL‐8 expression but 
does  not  affect  the  expression  of  other  microglial  cytokines  released  following 
microglial  activation  (Lokensgard  et  al.,  2000).  Microglia  in  the  presence  of  Thal 
acquired  a  rounded  activated  morphology  (Figure  4.3.4  B)  but  TNF‐α  was  not 












in  co‐culture  produced  similar  amounts  of  TNF‐α.  The  presence  of  6  DIV 
oligodendrocytes under inserts with microglia or in co‐culture with microglia also did 













cultured  OPCs  and  microglia  (Figure  4.3.8  A).  Incubation  with  increasing 
concentrations of AMT‐HCl did not block LPS induced OPC death and thus cells did 
not  differentiate  into  myelinating  oligodendrocytes  in  vitro  (figure  4.3.8  B).  3‐







co‐cultures  with  specific  agonists  and  antagonists  of  mGlu  receptors  30  minutes 
prior  to  LPS  administration.  The  cells  were  then  incubated  for  up  to  6  DIV.  The 
mGluR agonists and antagonists used were the group I agonist DHPG (100 μM), the 
group I antagonists AIDA (250 μM) and SIB‐1757 (50 μM) (mGlu5 specific), the group 
II  agonists  DCGIV  (500  nM)  and  NAAG  (50  μM)  (mGlu3  specific),  the  group  II 
antagonist APICA (200 μM), the group III agonists  LAP4 (100 μM) and RSPPG (100 
μM),  or  the  group  III  antagonist  MAP4  (500  μM).  None  of  these  agonists  or 












unconditioned  microglial  media,  conditioned  MGCM,  or  MGCM  treated  with  0.1 
μg/ml LPS. Direct addition of LPS to OPCs was not cytotoxic. MGCM did not induce a 
cytotoxic phenotype either; whilst LPS treated MGCM was protective to OPCs. This 
effect  was  attributed  to  soluble  factors  secreted  by  activated  microglia,  since 
unconditioned  media  alone  or  MGCM  did  not  protect  OPCs.  B.  Representative 



























was  assessed  by  live‐dead  staining.  Microglia  on  inserts  were  left  untreated  or 




















were  treated  with  0.1  mg/ml  LPS,  10  μg/ml  of  the  TNF‐α  synthesis  inhibitor 
thalidomide (Thal) or both. LPS activated microglia induced significant OPC cell death 
when  compared  with  non‐treated  OPC  death  levels  in  contact  with  microglia. 
Thalidomide  was  able  to  block  microglial  induced  OPC  death  when  the  two  cell 
populations were cultured together. The values shown represent the mean ± SEM of 












two  cell  populations  were  cultured  in  contact.  Representative  fluorescence 
microscopy images of cell viability of OPCs in co‐culture with microglia without or 















able  to  differentiate.  Thalidomide  blocked  the  microglial  induced  OPC  death.  A. 
Western  blot  of  MBP  expression  in  the  co‐cultures  after  6  DIV.  LPS  activated 
microglia killed the OPCs before they could differentiate into oligodendrocytes. B. 
Western blot of MBP expression in the co‐cultures after 6 DIV. Thalidomide blocked 
































































































of  four  experiments  performed  where  oligodendrocyte  cell  death  was  visually 
confirmed but western blotting for MBP did not always result in visible bands, thus a 
representative blot was analysed and presented.   139 
4.4  LPS  activated  microglia  were  toxic  to  6  DIV  oligodendrocytes  in  co‐
culture 
 


























survival  in  vitro  (Figure  4.4.3).  Addition  of  20,000  microglia  with  LPS  on  6  DIV 
oligodendrocytes resulted in oligodendrocyte death. 20,000 microglia rather than 




of  the  cells  was  preferred,  since  this  allowed  less  oligodendrocyte  basal  death 
(compare 4.4.3 to 4.4.4 A). 






the  two  cell  populations  were  co‐cultured.  As  shown  earlier  TNF‐α  release  from 





cultures,  TNF‐α  release  was  attenuated,  in  agreement  with  the  cell  viability 
experiments (Figure 4.4.5). 
   Oligodendrocyte death was also prevented if the co‐cultures were treated with 1 
mM  glutamate  (Figure  4.4.6).  1  mM  glutamate  is  a  physiologically  non‐relevant 











































































Figure  4.4.4  A  LPS  activated  microglial  toxicity  to  6  DIV  oligodendrocytes  was 
attenuated by TNF‐α synthesis inhibition 
6 DIV oligodendrocytes and microglia were co‐cultured at a ratio of 3:2 for 24 hours 





















































































2:3  for  24  hours.  Representative  fluorescent  microscopy  images  of  6  DIV 
oligodendrocytes stained with Hoechst (blue) and PI (red) with or without phase 
contrast. Co‐cultures were treated with 0.1 mg/ml LPS, 1 mM glutamate (Glu) or 
both.  LPS  activated  microglia  induced  6  DIV  oligodendrocyte  cell  death.  In  the 


















   Glutamate  was  administered  to  oligodendroglial  cells  of  different  maturation 
stages in an attempt to clarify the effect of glutamate excitotoxicity on these cells. 
The  effects  of  glutamate  to  oligodendroglial  cells  were  compared  with  CGCs,  an 
established  model  of  excitotoxicity  (Lowenstein  et  al.,  1991),  thus  allowing  the 
comparison of the results obtained for oligodendrocyte lineage cells with a ‘positive’ 
glutamate excitotoxicity model. The effects of glutamate to microglial cell toxicity 
were  also  studied.  The  glutamate  solution  was  made  fresh  in  distilled,  sterilised 
water  on  the  day  of  the  experiment  and  cells  were  incubated  with  increasing 
concentrations for 24 hours, after which they were stained live with Hoechst and PI 
to assess cell viability. 
   Glutamate  was  significantly  toxic  to  OPCs  above  100  μM  in  a  concentration 
dependent  manner  (Figure  4.5.1  A,B).  3  DIV  developing  oligodendrocytes  were 
vulnerable  to  glutamate  above  500  μM  in  a  concentration  dependent  manner. 
(Figure 4.5.1 A,B). 6 DIV oligodendrocytes were not vulnerable to glutamate at any 




















OPCs  (i),  3  DIV  developing  oligodendrocytes  (ii)  and  6  DIV  oligodendrocytes  (iii) 
stained with Hoechst (blue) and PI (red). Control, 100 μΜ glutamate and 1 mM 
glutamate images are shown. Scale bar = 20 μm. The values shown represent the 







Freshly  made  up  glutamate  was  added  to  CGCs,  an  established  model  of 
excitotoxicity,  and  the  cells  were  incubated  for  24  hours  before  cell  death  was 
assessed  by  live  staining.  CGCs  were  vulnerable  to  glutamate  in  a  concentration 
dependent manner and the plotted graph can be used to compare the effects of 
glutamate  on  an  established  model  (CGCs),  with  glutamate  toxicity  to 














stained  green  with  anti‐ED1  antibody.  Glutamate  treated  microglia  acquired  an 
activated morphology with rounded, brightly stained cytoplasm. Scale bar = 20 μm. 
Values shown represent the mean ± SEM of three experiments where three fields of 







shown  that  LPS  induced  OPC  death  was  TNF‐α  and  not  NO  mediated.  mGluR 
manipulation did not seem able to modulate that toxicity. Mature oligodendrocytes 
were  less  vulnerable  to  activated  microglia,  but  still  co‐culture  of  these  two  cell 
populations and LPS administration resulted in significant mature oligodendrocyte 
death.  The  properties  of  oligodendrocyte  lineage  cells  do  differ  with  the 
developmental  stage  of  the  cell  population.  Studying  the  effect  of  glutamate  on 
oligodendrocytes  further  supported  this.  It  was  confirmed  that  indeed  the 
vulnerability  of  the  cells  was  dependent  on  their  maturation  stage,  with  mature 









activated  microglia  was  shown  to  reduce  oligodendrocyte  apoptosis  in  vitro 
(Nicholas et al., 2002) by recruiting phosphatidyl‐3‐inositol kinase and increasing NF‐









survival  in  vitro.  It  has  been  shown  that  non‐activated  microglia  can  enhance 
neuronal survival up to 50% by acting on the mitogen‐activated protein kinase and 











medium  to  OPC  cells,  did  not  only  abolish  the  protective  effect  of  microglial 
conditioned medium, but induced OPC death (Pang et al., 2000).  It has to be noted 
though,  that  in  that  study  the  microglia  were  activated  with  1  μg/ml  LPS,  a 
concentration  tenfold  higher  than  the  one  used  here.  It  is  the  first  time  that  a 
protective effect to OPCs has been attributed to LPS activated microglial conditioned 
medium.  In  a  study  complementary  to  this  (Nicholas  et  al.,  2002),  IFN‐γ  treated 
microglial  conditioned  medium  increased  the  survival  of  CG‐4  cells  and 
oligodendrocytes.  There  were  no  significant  changes  to  cell  death  levels  when 
activated  microglial  conditioned  medium  was  used  to  culture  mature 












0.1  μg/ml  LPS  led  to  highly  significant  OPC  death  (Figure  4.3.4).  The  growth  of 
microglia on cell inserts with 0.4 μm pore size, allowing intercellular communication 
but  compartmentalising  the  cells,  again  resulted  in  OPC  death,  but  of  lesser 
statistical significance than the death induced in co‐culture.  These results clearly 
indicated that the presence of microglia was necessary for LPS non cell autonomous 
OPC  death.  The  attempts  to  elucidate  the  pathway  of  microglial  activation  that 
resulted into OPC death suggested TNF‐α as the soluble factor released by activated 
microglia responsible for OPC toxicity. Inhibition of TNF‐α synthesis with its synthesis 






effect  of  endogenous  TNF‐α  by  externally  administrating  it.  Additionally  it  was 




depolarisation  and  mature  oligodendrocyte  cell  death  after  microglial  activation 
(Domercq et al., 2007) and in contrast to a study that produced evidence towards a 
protective  role  for  LPS  activated  microglia  in  co‐culture  with  mature 
oligodendrocytes (Miller et al., 2007). The mature oligodendrocyte death was not as 








cell  death  only  in  co‐culture  and  not  via  conditioned  medium  transferred  from 
activated microglia to oligodendrocytes could involve cell contact and membrane 

















that  in  co‐culture  of  pure  microglia  with  immature  oligodendrocytes  the  death 
mechanism switched to a NO and peroxynitrite mediated mechanism as previously 
reported  (Li  et  al.,  2005).  An  earlier  study  had  also  suggested  that  microglia  kill 
immature oligodendrocytes via an NO mediated mechanism (Merrill et al., 1993). In 
mature  oligodendrocytes  it  was  shown  that  cells  were  specifically  killed  via 
peroxynitrite (Jack et al., 2007). In this study the use of the iNOS inhibitor AMT‐HCl 
did not rescue OPCs from microglial mediated death (Figure 4.3.8 B). Even though 
the  OPC  cell  cultures  were  highly  enriched  (92.8  +/‐  1.29),  with  the  majority  of   159 
contaminating cells being microglia, if the presence of astrocytes was responsible for 
protection against peroxynitrite and switch to the TNF‐α mediated mechanism, this 
would  probably  represent  the  in  vivo  situation  more  convincingly.  It  has  been 




























Thus,  group  III  mGluRs  offer  further  targets  for  controlling  microglial  toxicity  in 
neurodegenerative disease (reviewed by Pocock and Kettenmann, 2007). OPC death 
induced by microglial activation by LPS was not significantly modulated by the use of 









increased  concentrations  of  glutamate  (Oka  et  al.,  1993;  Yoshioka  et  al.,  1995; 
Matute et al., 1997;  McDonald et al., 1998; Li & Stys, 2000). Here it was observed 
that  glutamate  was  significantly  toxic  to  OPCs  and  developing  oligodendrocytes 
(Figure 4.5.1 A). Surprisingly, it was observed that even high, physiologically non‐
relevant  concentrations  of  glutamate  were  unable  to  induce  cell  death  of  6  DIV 




rendered  them  unable  to  respond  to  LPS  and  exhibit  toxicity  to  mature 
oligodendrocytes (Figure 4.4.6). 
   On closer inspection of the literature, it was noticed that in most studies where 
oligodendrocyte  toxicity  was  mentioned,  the  cells  under  investigation  were  pre‐
myelinating cells that had not been kept in culture long enough and were not proven 
to express myelin proteins (Oka et al., 1993; Matute et al., 1997; Deng et al., 2006; 

















but  in  mature  oligodendrocytes  only  GluR2  remained  (Itoh  et  al.,  2002).  Sole 
expression of GluR2 has been shown not to evoke a Ca
2+ current (Hollmann et al., 
1991;  Itoh  et  al.,  2002).  Kainate  receptor  subunits  were  also  downregulated  in 
mature  oligodendrocytes  (Rosenberg  et  al.,  2003).  It  was  believed  that 
oligodendrocytes  did  not  possess  NMDA  receptors,  but  recently  white  matter 
oligodendrocytes  of  all  developmental  stages  were  shown  to  express  functional 











MS,  such  as  EBV,  human  herpes  virus  6,  MS‐associated  human  endogenous   162 




   The  clinical  significance  of  this  chapter’s  finding  that  glutamate  is  toxic 
predominantly to developing oligodendrocytes is rendered important by studies that 
have  confirmed  elevated  levels  of  glutamate  in  MS.  In  the  CSF  of  MS  patients, 
glutamate  levels  were  found  elevated  during  relapses  or  in  patients  with  severe 
neurological defect (Stover et al., 1997; Barkhatova et al., 1998). Glutaminase, the 
enzyme that converts glutamine to glutamate, and glutamate transporter elevated 
levels  were  correlated  with  axonal  damage  in  MS  patient  tissue  (Werner  et  al., 
2001). Elevated glutamate could prevent remyelination in lesions by directly injuring 
developing  oligodendrocytes,  or  by  indirectly  contributing  to  mature 
oligodendrocyte death by its action on microglia and astrocytes. Thus, regulation of 













































is  35‐50  μg/ml)  but  following  BBB  breakdown,  albumin  can  enter  the  brain 
(Salahuddin et al., 1988; Sokrab et al., 1988; Butter et al., 1991; Kevil et al., 1998).  
   Elevated albumin concentrations in the CNS can exert diverse effects on brain cells. 
Astrocytes  respond  to  albumin  by  calcium  uptake  and  proliferation,  events 
resembling  astrocyte  response  to  CNS  damage  (Nadal  et  al.,  1996).  In  microglia, 
albumin can act as a signalling molecule, inducing an increase in cytoplasmic calcium, 
mediated  via  Src  tyrosine  kinases  and  phospholipase  C,  and  leading  to  calcium‐




glutamate  and  TNF‐α  release,  glutathione  production  and  was  implicated  in 
neurotoxic cascades following microglial activation (Hooper et al., 2009). Here the 





























through  intranasal  delivery  of  the  inhibitory  γ












2001),  tau,  MAP2  (Amano  et  al.,  2003),  GFAP  (Kosako  et  al.,  1997),  and 
neurofilaments (Hashimoto et al., 1998), that depolymerise upon phosphorylation. 
ROCK  regulates  actin‐myosin  contractivity  and  is  thus  implicated  in  cytoskeleton 
rearrangement and cell process retraction (reviewed by Mueller et al., 2005).  
    ROCK  inhibition  has  been  proposed  as  a  feasible  neurite  outgrowth  enhancing 
strategy.  In  spinal  cord  injury,  Rho‐ROCK  stimulation  by  the  trimeric 
NgR/p75
NTR/LINGO‐1 receptor complexes caused neurite growth inhibition (Mi et al., 
2004).  Neurite  outgrowth  was  promoted  when  ROCK  was  pharmacologically 
inhibited  (Lingor  et  al.,  2007).  In  Alzheimer’s  disease  inhibition  of  the  Rho‐ROCK 
pathway resulted in reduction of the amyloid fibril peptide Aβ42 levels (Zhou et al., 




that  has  Rho‐ROCK  inhibition  mediated  anti‐inflammatory  properties  is  being 
evaluated as a potential MS therapy (Paintlia et al., 2005; Miron et al., 2007). ROCK 
was  also  identified  as  a  key  factor  in  coordinating  Schwann  cell  myelination  by 
regulating myosin phosphorylation (Melendez‐Vasquez et al., 2004).   167 
   ROCK involvement in myelination, oligodendroglial survival regulation (Miron et al., 





















denaturing  western  blotting  (Figure  5.2.3).  Primary  microglia  were  also  activated 
with  FG  and  FN  in  serum  free  medium  and  iNOS  expression  was  detected  by 
immunostaining  (Figure  5.2.4  A)  and  western  blotting  (Figure  5.2.4  B).  iNOS 
expression of FG and FN activated microglia was comparable to iNOS expression of 
LPS activated microglia (Figure 5.2.4). 
   Finally,  TNF‐α  release  from  BBP  activated  microglia  was  assessed.  TNF‐α  was 
released  following  microglial  activation  with  LPS  (discussed  in  Chapter  4,  Figure 
























































μm.  B.  Representative  western  blot  (i)  and  densitometric  analysis  (ii)  of  iNOS 
expression  of  1  day  in  vitro  primary  microglia  after  24  hour  activation  with  FV 
albumin  (FV)  in  serum  free  medium.  1  mg/ml  FV  induced  iNOS  expression. 
Commercially  available  mouse  macrophage  LPS/IFNγ  cell  lysate  (BD  Transduction 
611473) was used as positive control. β‐actin was used as a loading control. The 



























was  stained  red  with  anti‐iNOS  antibody.  B.  Representative  western  blot  (i)  and 







Figure  5.2.5  FV  albumin,  fibrinogen  and  fibrin  induced  TNF‐α  release  from 
microglia in the presence of oligodendrocyte lineage cells 






















and  in  inserts  above  6  DIV  oligodendrocytes  or  in  co‐culture  with  6  DIV 
oligodendrocytes (B). Microglia were activated for 24 hours with 1 mg/ml FV, 2.5 
mg/ml FG, or 1 mg/ml FN. Comparisons between different experimental conditions 
following  microglial  activation  with  BBPs  were  made  for  OPCs  or  6  DIV 
oligodendrocytes. In co‐culture FN activated microglia released less TNF‐α (Aiii). This 












































60  min  at  4
oC  to  prevent  internalisation  and  to  ensure  that  the  observed 



























morphology.  Isolectin  BSI‐B4  was  used  to  selectively  stain  microglia  green  and 
distinguish them from OPCs. The fluorescence microscopy fields show FV treated 
microglia  and  OPCs  in  co‐culture  without  or  with  phase  contrast  stained  with 
Hoechst 33342 (blue), PI (red) and BSI‐B4 (green). Details of two activated microglia 
can be seen. The microglial cell on the right is phagocytic (spongiform). A bipolar 
























60  min  at  4
oC  to  prevent  internalisation  and  to  ensure  that  the  observed 
fluorescence was due to internalisation and not binding.
 Some cells were stained 






(Figures  5.2.3  and  5.2.4),  the  direct  effect  of  FG  on  oligodendrocyte  lineage  cell 
toxicity  was  investigated,  as  well  as  the  effect  of  FG  activated  microglia  on 
oligodendrocyte cell toxicity. 
   Initially, OPCs were incubated directly with 2.5 mg/ml FG for 24 hours. FG was not 
toxic  to  OPCs  as  assessed  by  live‐dead  staining  (Figure  5.3.2  A).  Furthermore, 
incubation with microglial‐conditioned medium from microglia incubated with 2.5 
mg/ml FG for 24 hours (FG‐MGCM) was protective to OPCs (Figure 5.3.2 B). This 

























Microglia  were  left  untreated  or  treated  for  24  hours  with  2.5  mg/ml  FG.  FG‐
activated  MGCM  was  protective  to  OPCs.  C.  OPCs  were  cultured  alone  (25,000 
cells/well)  or  with  addition  of  microglia  (25,000  cells/insert)  in  0.4  μm  pore  cell 
inserts above the OPCs for 24 hours and cell viability was assessed by live‐dead 
staining. Cells were untreated or treated with 2.5 mg/ml fibrinogen. FG induced OPC 
death  in  the  presence  of  microglia,  indicating  that  fibrinogen  induced  microglial 
activation was toxic for OPCs D. Microglia and OPCs were co‐cultured in contact at a 
ratio of approximately 3:2. The co‐cultures were left untreated or were treated with 
2.5  mg/ml  FG  for  24  h.  FG  induced  OPC  death  in  the  presence  of  microglia,  in 
contrast to when it was directly administrated to OPCs (A). Isolectin BSI‐B4 was used 





















toxicity  was  investigated,  as  well  as  the  effect  of  FN  activated  microglia  on 
oligodendrocyte cell toxicity. 
   Initially,  OPCs  were  incubated  directly  with  1  mg/ml  FN  for  24  hours.  FN  was 
significantly toxic to OPCs as assessed by live‐dead staining (Figure 5.3.3.1 A). OPCs 
were  incubated  with  50  μM  of  the  ROCK  inhibitor  Y‐27632,  which  was  able  to 
reverse FN‐induced toxicity. OPCs were preincubated for 24 hours with 50 μM of the 
ROCK inhibitor Y‐27632 (Maekawa et al., 1999) and then FN was added for another 
24  hours.  Cells  were  also  treated  with  Y‐27632  for  48  hours  to  assess  Y‐27632 
toxicity. ROCK inhibition by Y‐27632 prevented FN induced OPC death. The ROCK 
inhibitor  Y‐27632  was  significantly  toxic  to  the  cells  when  applied  alone,  but 
interestingly, in the presence of FN, its toxicity was no longer statistically significant 
(Figure 5.3.3.1 Α).  
   To  study  the  effect  of  FN  activated  microglia  on  OPCs,  microglial‐conditioned 



















and  OPC  specific  marker  NG2.  It  was  shown  that  only  in  control  cultures  OPCs 
differentiated into MOG expressing oligodendrocytes after 6 days in vitro (Figure 
5.3.3.2).  This  was  also  the  case  when  OPCs  were  cultured  in  the  presence  of 
microglia, where the persistence in the progenitor state was more obvious, since 
microglia  prevented  FN‐induced  toxicity  to  OPCs  and  allowed  them  to  be 
morphologically distinguished from BSI‐B4 stained microglia in co‐culture. FV and FG 
had  no  effect  on  oligodendrocyte  maturation  (Figure  5.3.3.3  A).  This  was  also 
confirmed with western blotting of co‐cultures for the expression of the mature 
oligodendrocyte marker MBP in the presence or absence of FN, FG or FV. Indeed 



















the  presence  of  microglia  on  inserts.  D.  Microglia  and  OPCs  were  co‐cultured  in 
contact. The co‐cultures were left untreated or were treated with 1 mg/ml FN for 24 
hours. FN did not induce OPC death in the presence of microglia, in contrast to when 




selectively  stain  microglia  green  and  distinguish  them  from  OPCs.  Details  of  two 





































DIV  OPCs  in  control,  FV  and  FG  treated  cultures  differentiated  into  mature 
oligodendrocytes.  FN  treated  OPCs  did  not  differentiate  into  mature 
oligodendrocytes, but rather persisted in a bipolar or late progenitor stage with a 
















hours.  FV  was  not  toxic  or  protective  to  OPCs  as  assessed  by  live‐dead  staining 
(Figure  5.4.1  A).  To  study  the  effect  of  FV  activated  microglia  on  6  DIV 
oligodendrocytes, microglial‐conditioned medium activated with 1 mg/ml FV (FV‐















for  24  hours  (C)  or  were  co‐cultured  in  contact  with  microglia  at  a  ratio  of 
approximately 3:2. Cell viability was assessed by live‐dead staining. Cells were left 
untreated  or  treated  with  1  mg/ml  FV.  FV  did  not  affect  6  DIV  oligodendrocyte 
viability  when  administered  to  the  cells  directly  (A),  when  used  to  condition 
microglial  conditioned  medium  for  24  hours  and  then  applied  to  the 
oligodendrocytes  (B),  when  added  to  6  DIV  oligodendrocytes  in  the  presence  of 
microglia  in  inserts  (C)  or  in  the  presence  of  microglia  in  contact  with  the 
oligodendrocytes (D). In all cases the graphs (i) represent the percentage of the total 
number of cells in OPC cultures that were late apoptotic following Hoechst 33342 













by  live‐dead  staining  (Figure  5.4.2  A).  2.5  mg/ml  FG  were  also  used  to  activate 
microglia, since this concentration was shown to activate microglia in vitro and cause 
iNOS expression (Figures 5.2.3 and 5.2.4). Incubation of 6 DIV oligodendrocytes with 
microglial‐conditioned  medium  (FG  MGCM)  was  protective  to  6  DIV 
oligodendrocytes  (Figure  5.4.2  B).  This  was  also  the  case  when  microglia  were 










administration  of  FG  to  6  DIV  oligodendrocytes  (Figure  5.4.2  A),  suggestive  of  a 
modulatory role for microglia present in co‐culture, although it was inefficient at 
completely protecting oligodendrocytes. It was also observed that in control cultures 




















































(Figure  5.4.3  A).  1  mg/ml  FN  was  also  used  to  activate  microglia,  since  this 
concentration was shown to activate microglia in vitro and cause iNOS expression 
































oligodendrocytes  (A).  The  presence  of  activated  microglia  protected  6  DIV 
oligodendrocytes  against  direct  FN‐induced  toxicity.  Isolectin  BSI‐B4  was  used  to 
selectively stain microglia green and distinguish them from 6 DIV oligodendrocytes. 
Microglia  were  activated  by  FN,  as  confirmed  by  their  morphology.  The 































      Direct   MGCM  MG in inserts  MG in contact 
OPCs  no effect  protective  toxic  toxic 
LPS 
6 DIV OL  no effect  no effect  no effect  toxic 
OPCs  toxic  no effect  toxic  no effect  FV 
albumin  6 DIV OL  no effect  no effect   no effect  no effect 
OPCs  no effect  protective  toxic  toxic 
Fibrinogen 
6 DIV OL  toxic  protective  protective  toxic 
OPCs  toxic  no effect  toxic  no effect 
Fibrin 






















than  LPS  induced  levels  (Hooper  et  al.  2009a).  These  results  suggest  that  the 
presence of serum in the culture medium desensitizes the receptors to which the 
activator proteins bind, or masks the sites of binding, thus not allowing protein‐
receptor  interactions.  It  has  been  shown  that  serum  affects  the  resting  state  of 








   FV  was  shown  to  be  directly  toxic  to  OPCs  (Figure  5.3.1.1).  The  presence  of 
microglia in contact with OPCs was able to protect OPCs from FV induced toxicity 








al.,  2005).  Src  signalling  was  recently  involved  in  fibrillary  Αβ  internalisation  by 
microglia (Reed‐Geaghan et al., 2009). It was also shown that mice deficient in all Src 
kinases exhibited impaired bacterial clearance following infection (Paul et al., 2008).      
































al.,  2000).  A  study  in  peripheral  nerve  injury  in  mice  showed  that  plasminogen 


















other  molecules  present  in  the  extracellular  space  following  brain  injury  or 
demyelination have also been implicated in OPC differentiation inhibition. The most 
prominent  of  these  factors  is  hyaluronan.  Hyaluronan  is  a  glycosaminoglycan 
composed  of  multiple  disaccharide  units  of  glucuronoic  acid  and  N‐
acetylglucosamine. It was found that high molecular weight hyaluronan synthesised 
by  astrocytes  accumulated  in  demyelinated  chronic  MS  lesions  and  inhibited 






al.,  2000).  Thus,  an  explanation  for  OPC  failure  to  differentiate  into  mature 
myelinating oligodendrocytes in chronic MS lesions is that the lesion environment is 










presence  of  a  non‐permissive,  or  even  developing  (like  in  the  case  PSA‐NCAM) 
environment. The clinical significance of these findings might lead to therapeutic 
practices  aiming  at  clearing  the  demyelinating  lesions,  thus  allowing  successful 
differentiation  of  OPCs  into  myelinating  cells.  It  was  shown  in  vivo  that  tissue 
plasminogen activator (tPA), a protease that converts plasminogen to plasmin, which 
in  turn  degrades  fibrin,  protected  axons  from  degeneration  and  demyelination, 
which correlated with increased deposition of fibrinogen (Akassoglou et al., 2000; 






levels  by  30%,  whilst  FV  induced  15%  increase  in  cell  death  after  24  hours  of 































revealed  in  this  study  resembled  microglial  activation  by  LPS  (Chapter  4),  as 
summarised and compared with the effects of the other BBPs studied in Table 5.5.1. 
















observed  following  microglial  activation  with  LPS,  suggesting  that  FG  may  act 
through a distinct receptor on microglia. It was shown that FG binds to the Mac‐1 








FG  activated  microglial  conditioned  medium  retained  its  protective  properties 
towards 6 DIV oligodendrocytes as well. Furthermore when 6 DIV oligodendrocytes 
were  cultured  below  microglia  in  inserts,  microglia  were  protective.  Conversely, 
















remyelination.  Breakdown  of  polymers  such  as  FN  accumulating  in  lesions  could 
potentiate OPC differentiation into newly myelinating oligodendrocytes. Modulation 
of  microglial  activation  following  BBP  activation  could  also  be  beneficial  by 
































disease  (see  5.1.3  and  1.5.3  respectively).  Furthermore,  based  on  concerns  that 
microglial  activators  other  than  the  prototypical  pathogen‐associated  molecular 






   As  discussed  in  5.1.3,  ROCK  is  a  Rho‐GTP  binding  kinase  with  numerous 
downstream  effectors  and  is  actively  implicated  in  regulating  actin‐myosin 
contractility.  ROCK  inhibition  has  been  proposed  as  a  feasible  neuroprotective 
strategy in neurodegeneration (reviewed by Mueller et al., 2005).  
   The  Rho‐ROCK  pathway  exists  in  all  cell  types  (Nakagawa  et  al.,  1996).  In 
macrophages the Rho‐ROCK pathway is involved in cytoskeleton rearrangement and 
migration  (Allen  et  al.,  1997),  as  well  as  in  complement  mediated  phagocytosis 












investigated.  It  has  been  shown  that  direct  stimulation  of  the  group  II  mgluR2 
receptors in microglia can trigger the release of TNF‐α, which in concert with soluble 
Fas ligand can be neurotoxic (Taylor et al., 2005), it is thus clear that glutamate can 
act  upon  microglia  and  elicit  a  signalling  response.  At  the  same  time  a 
neuroprotective  role  has  been  attributed  to  group  III  mGluRs,  again  providing 
evidence  that  activation  of  these  receptors  does  alter  microglial  responses. 
Manipulation  of  this  regulatory,  slow  metabotropic  response  could  lead  to 
therapeutic  strategies  when  addressing  diseases  with  a  neurodegenerative 
component.  










   It  was  recently  reported  that  many  commercially  available  reagents,  such  as 
plasma‐derived proteins, phospholipids and peptides, were contaminated with LPS 
(Weinstein et al., 2008). Thus, responses attributed to microglial activators other   210 




A6272)  as  well  as  the  effect  of  other  serum  derived  proteins  on  microglial 




kit  (LAL  Pyrochrome,  Associates  of  Cape  Cod  Incorporated)  reported  significantly 
high  levels  of  endotoxin  in  the  FV  reagent  used  in  this  study  (>0.43  EU/ml  in  1 
mg/ml). Here, it was investigated whether the BBPs used to activate microglia in this 





   BV‐2  cells  or  primary  microglia  were  incubated  for  24  hours  with  the  ROCK 
inhibitor Y‐27632 followed by 24 hour activation with LPS, FV, FG or FN. Lysates were 
collected and western blotting was performed for iNOS expression visualisation.  
   A  preliminary  experiment  in  BV‐2  cells  showed  that  1  μg/ml  LPS‐induced  iNOS 
expression was attenuated by 50 μΜ Y‐27632 (Figure 6.2.1 A). This experiment was 
repeated in primary microglia, where 50 μΜ Y‐27632 reduced 0.1 μg/ml LPS‐induced 


































hour  activation  with  1  μg/ml  LPS  in  serum  free  medium.  LPS  induced  iNOS 
expression  in  BV‐2s  showed  decreased  expression  following  50  μM  Y‐27632 








































used  as  a  loading  control.  B.  Representative  western  blot  (i)  and  densitometric 
analysis (ii) of iNOS expression of primary microglia after incubation for 24 hours 
with  the  ROCK  inhibitor  Y‐27632  at  50  μM  concentration  followed  by  24  hour 
activation with 2.5 mg/ml FG in serum free medium. Y‐27632 partially blocked iNOS 













incubation  for  24  hours  with  the  ROCK  inhibitor  Y‐27632  at  (50‐100)  μM 












    To  study  the  effect  of  mGluR  agonists  and  antagonists  on  iNOS  expression 
following microglial activation with LPS or BBPs, BV‐2 cells or primary microglia were 
activated  with  LPS  or  BBPs  for  24  hours  in  the  presence  of  mGluR  agonists  and 
antagonists. The agonists and antagonists were always added 30 minutes before the 
microglial activators, to allow them to bind to their receptors and initiate cellular 
responses  (Taylor  et  al.,  2002).  Lysates  were  collected  following  24  hours  of 
incubation and western blotting was performed on the cytoplasmic fraction.  
    Before  studying  the  effect  of  mGluR  agonists  and  antagonists  on  activated 
microglia, iNOS expression following 24 hour direct incubation of BV‐2 cells with the 














2s  in  combination  with  the  group  III  mGluR  antagonist  MAP4  (500  μM),  iNOS 
expression was strongly upregulated (Figure 6.3.2 A). This suggested that MAP4 can 
enhance FV induced toxicity in BV‐2s and was in agreement with evidence for a 
neuroprotective  role  for  the  group  III  mGluRs  (Taylor  et  al.,  2003).  Additionally, 
combination of FV with the group II mGluR agonists DCGIV (500 nM) or NAAG (50 
μM),  upregulated  iNOS  expression,  pointing  towards  a  mechanism  that  could   217 
enhance FV induced toxicity in BV‐2s (Figure 6.3.2 A). This agreed with evidence 
about group II mGluR induced neurotoxicity to microglia (Taylor et al., 2005).  
   Due  to  the  large  amount  of  primary  microglia  needed  to  collect  substantial 
cytoplasmic protein to run western blots and due to limitations on primary microglial 
availability,  based  on  the  FV  activated  BV‐2  cell  observations,  only  the  mGluR 
agonists  DCGIV  and  NAAG,  and  the  antagonist  MAP4  were  studied  in  primary 
microglia.  The  results  obtained  following  activation  of  primary  microglia  with  1 





BV‐2s  in  combination  with  the  group  I  agonist  DHPG  (100  μM),  the  group  I 








in  slight  increase  in  iNOS  expression  after  24  hours  in  vitro  (Figure  6.3.4  A).  In 
primary  microglia,  the  group  II  agonists  DCGIV  and  NAAG  and  the  group  III 












































expression.  Group  II  mGluR  agonists  DCGIV  and  NAAG  (mGlu3  specific)  also 
enhanced FV induced iNOS expression. LPS 1 μg/ml was used as an internal positive 
control. The blots represent experiments repeated in triplicate. B. Representative 




macrophage  LPS/IFNγ  cell  lysate  (BD  Transduction  611473)  was  used  as  positive 

















































































































Experiment  Sample  #1   EU/ml   #2    EU/ml 
1  Negative control  0.075   
  LPS 5 μg/ml  0.166   
  FV Albumin 50 mg/ml  0.197   
  FV Albumin 20 mg/ml  0.183   
  FV Albumin 1 mg/ml  0.152   
  FV Albumin 0.5 mg/ml  0.154   
  FV Albumin 0.25 mg/ml  0.123   
2  Negative control  0.021   
  LPS 1 μg/ml  0.268   
  FV Albumin 12 mg/ml  0.292  0.261 
  FV Albumin 2 mg/ml  0.262  0.294 
  FV Albumin 1 mg/ml  0.282  0.278 
3  Negative control  0.007  0 
  LPS 1 μg/ml  0.941  0.853 
  Distilled water  0.961   
4  Negative control  0   
  Distilled water  0.756   
  LPS 0.5 μg/ml  0.996   
  LPS 0.25 μg/ml  0.914   
  FV Albumin 12 mg/ml  0.945  0.967 
  FV Albumin 2 mg/ml  0.961  1.002 
  FV Albumin 1 mg/ml  0.941  1.010 
  Fibrinogen 2.5 mg/ml  0.966  0.996 
  Fibrin 1 mg/ml  1.005  0.978 











samples  were  tested  in  duplicate.  All  samples  tested,  as  well  as  UV  irradiated, 
filtered distilled water, were shown to contain high endotoxin levels, similar to those 






BBPs  could  bind  to  and  study  whether  those  receptors  were  identified  as  LPS 
receptors  as  well.  This  could  help  elucidate  the  issue  of  whether  different  BBPs 
activate microglia through distinct or identical to LPS pathways.  
   LPS  activates  microglia  by  binding  to  toll‐like  receptors,  predominantly  toll‐like 
receptor 4 (TLR4), and initiates the microglial immune response (reviewed by Olson 
& Miller, 2004). LPS binding to TLR4 triggers the dimerisation of the receptor and the 






















and  not  FN  as  previously  shown  (Adams  et  al.,  2007),  anti‐CD11b  was  able  to 
attenuate FG induced iNOS expression in BV‐2s. A slight increase in FV induced iNOS 




observations  could  be  made.  Addition  of  anti‐CD11b  to  LPS  activated  BV‐2s 
increased  TNF‐α  release.  FG  induced  release  of  TNF‐α  was  also  increased.  This 
increase in TNF‐α release could be explained by ligation of the CD‐11b receptor in 
the presence of the blocking antibody, which with its two antigen binding sites could 
bind  to  two  CD‐11b  receptor  domains  and  bring  them  in  close  proximity,  thus 




CD11b  antibody  reduced  FG  but  not  FN  induced  iNOS  expression  (Figure  6.5.3). 










atibody.  As  in  the  case  of  TLR4,  CD11b  blockage  upregulated  other  microglial 











Anti‐TLR4  attenuated  LPS  induced  iNOS  expression.  FV,  FG  or  FN  induced  iNOS 
expression was not reduced by anti‐TLR4, indicating that microglial activation by 
those  BBPs  is  not  dependent  on  the  TLR4  receptor.  Interestingly,  anti‐TLR4 
incubation increased iNOS expression in FV and FG activated microglia. β‐actin was 
used as a loading control. The LPS and FV experiments were repeated in duplicate. 











proteins  was  CD11b  independent.  A  slight  increase  in  FV  induced  iNOS  in  the 
presence  of  CD11b  was  observed.  Commercially  available  mouse  macrophage 
LPS/IFNγ cell lysate (BD Transduction 611473) was used as positive control. β‐actin 
was  used  as  a  loading  control.  B.  Medium  from  the  experiment  on  BV‐2s  was 
collected  and  TNF‐α  release  was  measured  with  an  ELISA  kit.  The  kit  used 
(Quantikine Rat TNF‐α, R&D Systems, Oxford, UK) was rat specific so with BV‐2 cells 






















BBPs,  involvement  of  potential  receptors  in  BBP  mediated  microglial  activation, 
intracellular  pathways  mobilised  following  activation  and  the  potential  of 













glutamate  receptors)  are  implicated  in  iNOS  upregulation  following  microglial 
activation primarily with FV. mGluRs could modulate iNOS expression via AC (adenyl 








microglia  though,  Y‐27632  could  only  partially  downregulate  iNOS  expression 





expression  via  Rho  mediated  pathways  that  may  or  may  not  depend  on  ROCK 
activation, or by a completely distinct, Rho‐ROCK independent pathway.  
   The  Rho‐ROCK  pathway  in  macrophage  lineage  cells  is  implicated  in  actin 
regulation,  process  formation  and  migration  (Allen  et  al.,  1997),  as  well  as  in 
complement‐mediated phagocytosis (Caron & Hall, 1998). RhoA or ROCK depletion 
was  involved  in  cyclooxygenase‐2  (COX‐2)  related  anti‐inflammatory  processes  in 
spinal  cord  lesions  (Schwab  et  al.,  2004).  Cytoskeleton  rearrangement  and 
inflammatory processes, the two cellular functions with which Rho‐ROCK has been 
associated,  are  linked  by  phagocytosis,  a  process  that  requires  rapid  actin 
rearrangement and is associated with external cell signalling (reviewed by Chimini & 
Chavrier, 2000). ROCK inhibition might thus be a promising target for modulating 









viable  therapeutic  strategy  for  attenuating  microglial  activation  and  ameliorating 
toxic effects on neurones and oligodendrocytes in MS. The upregulation of iNOS in 




could  reduce  sustained  microglial  activation  and  protect  neurones  and 
oligodendrocytes in chronic activation conditions, such as in progressive MS lesions. 










possible  that  mGluR  interference  in  iNOS  upregulation  may  be  triggered  by 
phagocytosis. Even though there are no data supporting modulation of phagocytosis 









   Microglia  recognise  pathogen‐derived  ligands  via  binding  of  conserved  pattern‐









result  which  suggests  that  the  TLR4  blocking  antibody  may  promote  TLR4 
dimerisation  by  bringing  two  molecules  of  the  TLR‐4/MD‐2  complex  (Park  et  al., 
2009) in close proximity, thus resulting in cellular responces such as iNOS expression. 
Thus, even though the LAL endotoxin kit revealed high levels of endotoxin in the BBP 






integrin  receptor  subunit  CD11b  is  the  macrophage  receptor  for  FG  (Ugarova  & 
Yakubenko, 2001; Lishko et al., 2002). In this study a decrease in iNOS expression 
following FG but not FN activation of microglia was observed by blocking the CD11b 
receptor  (Figure  6.5.3).  That  was  not  the  case  for  TNF‐α  release,  which  was 
upregulated after CD11b blockage in both FG and FN activated microglia (Figure 
6.5.3).  Again,  this  may  result  from  the  anti‐CD11b  antibody  binding  with  two 
different  CD11b  receptors,  promoting  their  dimerisation  and  possibly  activating 
intracellular pathways resulting in TNF‐α release. Also, even though there is data 
supporting  CD11b  activation  as  the  primary  event  of  FG  mediated  microglial 
activation, the possibility that there may be additional microglial receptors to which 
FG may bind should not be ruled out. For example, FG has been shown to bind to 
intercellular  adhesion  molecule‐1  (ICAM‐1)  on  endothelial  cells,  a  molecule  that 
signals through the Rho‐GTPase pathway (Tsakadze et al., 2002). Furthermore, TRL2   237 
receptor,  which  binds  lipoproteins,  peptidoglycans  and  polymeric  molecules 
(Lehnardt, 2009), is a promising candidate for FG and FN ligation. 









TLR4,  the  results  obtained  by  FV  activation  of  BV‐2s,  showing  a  significant 
upregulation of iNOS by group II mGluR agonists DCGIV and NAAG and group III 
mGluR antagonist MAP4 (Figure 6.3.2), were not replicated with LPS. 
   To  conclude  the  discussion  on  whether  BBP  observed  effects  on  microglia  are 





detailed  comparison  of  the  effect  of  LPS,  FV,  FG  or  FN  activated  microglia  in 
oligodendrocyte lineage cell viability was made. It thus revealed many differences 
between the microglial activators (summarised in Table 5.5.1), as well as interesting 
similarities  between  LPS  ‐  FG  or  FV  ‐  FN,  pointing  towards  membrane  receptor 
mediated  microglial  activation  by  LPS  and  FG,  and  internalisation  mediated 












mGluRs  as  modulatory  targets  is  based  on  studies  revealing  their  neurotoxic  or 
neuroprotective effects in vitro (Taylor et al., 2003; Taylor et al., 2005; Pinteaux‐
Jones et al., 2008) or in vivo (Corti et al., 2007) and is complemented by the fact that 



























MS  lesions  is  well  documented  in  all  disease  stages,  such  as  the  newly  defined 
preactive lesions (Gay et al., 1997; De Groot et al., 2001), the active, demyelinating 
lesions where microglia phagocytose debris and facilitate regeneration (Takahashi et 
al.,  2005;  Piccio  et  al.,  2007;  Nielsen  et  al.,  2009),  as  well  as  in  chronic 



















oligodendrocyte  lineage  cells  were  cultured  together.  On  the  contrary,  when 
microglia  were  activated  with  FG  and  medium  collected  following  a  24  hour 
activation  was  applied  on  oligodendrocytes,  the  effect  was  protective  and   241 
oligodendrocytes survived better. Thus, soluble, stable factors that are released from 
microglia may be protective to oligodendrocytes that are not in close proximity to 
microglia  in  MS  lesions,  whilst  when  microglia  migrate  near  cells,  additional 




the  presence  of  exposed  myelin.  Microglia  migrate  to  the  sites  of  degeneration 




has  culminated.  The  action  of  FG  on  microglia  resembled  the  results  obtained 
following microglial activation with LPS, particularly when studying toxic effects on 















   FV  and  FN  also  exhibited  distinct  functions  with  interesting  similarities.  Both 
proteins  were  directly  toxic  to  OPCs  but  their  toxicity  was  ameliorated  when 
microglia were added to the OPC cultures. This indicated that microglia could clear   242 
FV or FN from the area around OPCs and thus protect them from the toxic effects of 















was  particularly  obvious  when  OPCs  were  cultured  in  co‐culture  with  microglia, 
where microglia prevented FN induced OPC death. In acute MS lesions, where there 
is BBB disruption (Claudio et al., 1995; Wakefield et al., 1994), the presence of FN 
may  have  adverse  effects  for  disease  progression  by  contributing  to  the  well 
documented presence of quiescent or proliferating, but not differentiating OPCs in 










molecules  are  high  molecular  weight  polymers,  or  in  the  case  of  myelin  lipidic 
membrane structures. This suggests that there may be a common mechanism by 
which these high molecular weight molecules can act upon OPCs and preserve them 
in  an  immature,  proliferating  stage.  This  finding  has  implications  for  disease 
pathology in MS and contributes to explain remyelination failure. Strategies that 
could  remove  FN  from  MS  lesions  or  pharmacologically  inhibit  the  intracellular 



















induced  OPC  death,  all  mGluR  agonists  and  antagonists  available  were  used  on 
microglia  in  conjunction  with  LPS  to  try  and  ameliorate  the  toxic  effect  of  LPS 
activated microglia on OPCs. None of the agonists or antagonists were able to do 
that. Still, a promising area of research is that of glutamate induced OPC death. It 
was  shown  here  that  OPCs  and  developing  oligodendrocytes  but  not  mature 
oligodendrocytes  were  vulnerable  to  glutamate.  It  would  be  interesting  to 
investigate whether glutamate induced OPC death could be prevented by mGluR 





regulatory  role  for  mGluR  receptors  in  MS  lesions.  On  the  other  hand  mature 
oligodendroytes have only been shown to express mGluR3 (Luyt et al., 2006). Thus if   245 
a  regulatory  role  for  microlial  mGluRs  in  oligodendrocyte  toxicity  is  revealed, 
therapeutic  avenues  directly  targeting  microglia,  OPCs  and  neurones  could  be 
developed. 
   Another  field  that  deserves  further  studying  is  that  of  differentially  activated 





α  in  conjunction  with  cell  contact  was  identified  as  the  secreted  molecule 
responsible  for  microglial  mediated  cell  death,  similar  experiments  should  be 
performed  to  elucidate  BBP  mediated  oligodendrocyte  death.  Identification  of 
different  protective  or  toxic  cytokines  released  following  differential  microglial 
activation would complement this study. Furthermore, a lot of work could be done 
to identify the microglial receptors of BBPs. Having excluded BBP signalling via the 
LPS  receptor  TLR4,  the  question  of  which  receptors  they  act  though  remains 
unanswered. Even FG, which has been shown to signal via CD11b (Adams et al., 
2007), seems to further bind to other receptors. As suggested in chapter 6, TRL2 
receptor,  which  binds  lipoproteins,  peptidoglycans  and  polymeric  molecules 
(Lehnardt, 2009), is a promising candidate for FG and FN ligation.  
   Finally,  in  regards  to  the  BBP  studies,  the  finding  that  FN  arrests  OPC 
differentiation  should  be  studied  further.  Molecular  pathways  implicated  in  this 
mechanism could be studied, and some ideas on which pathways might be involved 
could be derived from previous studies investigating OPC arrest (Akassoglou et al., 
2004;  Kotter  et  al.,  2006).  The  exact  developmental  stage  at  which  OPCs  are 
preserved when FN is present can be identified by investigating the expression of 
genes  indicative  of  different  OPC  maturation  stages.  There  is  a  wealth  of  such 
‘developmental’ markers available (Linington et al. 1984;  1988; Nishiyama et al., 







in  MS  and  its  effects  on  oligodendrocyte  lineage  cell  viability  and  maturation.  It 
opened  new  avenues  with  the  identification  that  the  blood  borne  proteins  FV 
albumin,  fibrinogen  and  fibrin  are  able  to  potently  and  differentially  activate 
microglia and to induce distinct effects on OPCs or mature oligodendrocytes. It was 
the first time that a toxic effect to oligodendrocyte lineage cells was attributed to 
blood‐borne  proteins  and  the  first  time  that  a  blood‐borne  protein  (fibrin)  was 
implicated in myelination failure. Also, new views were added to conflicting issues 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